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ABSTRACT
The fundamental vibrational modes of biological constituents in the tissues and the
complex body fluids coincide with optical frequencies in the infrared region. Therefore, spatially
resolved molecular compositions and interaction information within the biological materials can
be extracted non-destructively using IR radiation without the use of labels or probes. However, the
feasibility of this technique to elucidate constituent molecular compositions and interactions within
the diagnostic mediums is not well explored. This study demonstrates an application of infrared
(IR) spectroscopy of sera for monitoring inflammatory bowel diseases (IBD) and various cancers.
Using samples from experimental mice and human patients, the power of IR spectroscopy in
structural studies of proteins and other complex band contours are explored to find spectral
signatures.
Two experimental models of IBD; interleukin 10 knockouts (IL10-/-) and Dextran Sodium
Sulfate (DSS) induced mouse shows diagnostic accuracy with 80-100% sensitivity and specificity
values. Importantly, the findings of human IBD patients’ serum also show promising results
resembling our proofs-of-concept investigations of mouse models. Maximum values of sensitivity
and specificity are 100% and 86%, respectively, in human samples. Similarly, in cancer studies,
the EL4 mouse model of non-Hodgkin lymphoma (NHL) and a B16 mouse model of the
subcutaneous melanoma are used to extract a snapshot of tumor-associated alteration in the serum.
The study of both cancer-bearing mouse models in wild types (WT) and their corresponding
control types emphasizes the diagnostic potential of this approach as a screening technique for the
NHL and melanoma skin cancer. The breast cancer (BC) -associated protein conformational
alteration in the serum samples shows the sensitivity and the specificity of identifying spectral
signatures were both 90%. All in all, IR spectroscopy of serum samples accompanied by spectral

analysis technique shows some promising results for disease diagnostics. The brief outlook of the
fundamentals of the infrared detection technique and their applicability for the development of
portable spectroscopy is also provided.
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INTRODUCTION

Spectroscopic techniques are becoming popular exploratory tools to investigate the
interaction between matter and electromagnetic radiations[1]. The popularity is due to the
extraordinary sensitivity of spectroscopy to understand the molecular structures depending on
bonding between the constituent atoms and their spatial arrangements. Based on the nature of the
measurement process, radiative energy involved in the interaction and their applications, these
techniques are classified into several types[2]. These include classification based on atomic or
molecular probing, electronic or magnetic features, Gamma to terahertz radiation, absorption or
emission of radiations, and many more. The selection of an individual spectroscopic technique
depends on the purpose of the study. Among these several spectroscopic techniques, the infrared
spectroscopy is applicable to investigate vibrational and the rotational motions of molecular bonds
and the spatial arrangement of the constituent atoms[3]. The usefulness of infrared spectroscopy
arises due to the unique spectral fingerprint of each molecule type.
In this dissertation, infrared spectroscopy is utilized to investigate the structural and
compositional features of constituents in serum samples and disease-associated alterations within
them. Accompanied by data analysis techniques, Fourier transforms infrared (FTIR) spectroscopy
of sera has been explored to find disease-associated alterations in the constituent’s
biomolecules[3]. The FTIR uses interferometry to record information about the material and these
interferograms are being decoded into recognizable spectra via Fourier transformations. The first
part of the dissertation investigates the feasibility of the technique to understand inflammatory
bowel diseases (IBD) associated alteration in the serum samples of experimental mice[4-11] and
human patients. In experimental models, acute (Dextran Sodium Sulfate induced: DSS) and
chronic (Interleukin 10 knockouts; IL10-/-) mice are tested. Arthritis (Collagen Antibody Induced
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Arthritis: CAIA) and metabolic syndrome (Toll-Like Receptor 5 knockouts: TLR5) models are
also tested as controls[4, 5]. The second part of the dissertation investigates its potential to
discriminate cancer-associated changes in the serum samples[12, 13]. In the cancer study, an EL4
mouse model of non-Hodgkin lymphoma (NHL) and a B16 mouse model of the subcutaneous
melanoma are used[12]. The samples of Breast cancer (BC) patients were also used to investigate
the feasibility of the technique[13]. An outlook on the ongoing study of the standardization of
technique for the acquisition of spectral signatures applicable in the clinical domain and preparing
unique database is also discussed.
1.1

Fourier Transforms Infrared (FTIR) Spectroscopy

The interaction of light with matter depends on the nature of the material, the wavelength
of the incident light, and the intensity[14]. Within the infrared region of the electromagnetic
spectrum, as light interacts with matter and the chemical bonds will stretch, contract and bend. It
is because different bonds and functional groups of constituents have a range of quantized
vibrations and bending modes. When these constituent molecules are irradiated with infrared
photons matching the energy of those vibrational energy levels, molecules absorb the radiation
and start to vibrate. As a result, the amplitude of the vibration (which depends on intensity) is
increased, but it does not affect the frequency of those vibrations and remains the same[15].
Therefore, a chemical functional group tends to adsorb infrared photons/radiation in a specific
wavelength region, regardless of the structure of the rest of the molecule. The analytical technique,
which measures the vibration characteristics (i.e. Infrared intensity versus the wavelength or
wavenumber of light) of chemical functional groups in the sample is called infrared
spectroscopy[3].

3
FTIR spectrometer obtains infrared spectra by first collecting an interferogram of the
sample that measures IR frequencies simultaneously, and digitizes it followed by performing the
Fourier transformation[16]. It takes advantage of how IR light changes the dipole moments of
molecules at the specific vibrational energy (𝐸 = ℎ𝜐 = ℎ 𝑐⁄𝜆 = ℎ𝑐𝜐̅ , where c is the velocity of
light and h is Planck’s constant) corresponding to reduced mass (µ) and the bond spring constant
(k)[17];
1

𝑘

𝜐̅ = 2𝜋 √𝜇

…………. (1)

Figure 1.1 (A) The schematic of FTIR spectroscopy. The infrared (IR) detector receives
an interferogram, and our computer does the Fourier transformation to generate the absorbance
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spectrum. It simultaneously collects data over a wide spectral range, reflecting how much light is
absorbed by a sample at each wavelength. (B) Different sampling modes of FTIR spectroscopy,
including transmission, transflection, and the attenuated total reflection (ATR).

Figure 1.1 (A) shows the schematic of an FTIR spectrometer. The Michelson
interferometer modulates the incoming optical radiation by changing the optical path difference
between the two possible paths. Thus, formed interferograms are the coded representation of the
target spectrum. Fourier transformation decodes the interferogram and provides the spectrum of
the target radiation. In biochemical research, FTIR spectroscopy is a powerful analytical tool that
can be used to provide insight into the composition, structure, and interaction of constituent
molecules within biological solutions[18, 19]. Changes in the characteristics of biological fluids
that often occur in disease can be detected in spectral data and have emerged as a robust tool used
in clinical[20] and forensic[21] studies.
An increasing number of studies have demonstrated the effectiveness and promising
application of this technique in several applications in the broad field of biological sciences[22].
The frequencies and their biochemical assignments of prominent spectral bands are also
identified[23]. Standard protocols for the measurement of diagnostic mediums using FTIR
spectroscopy[24] and spectral analysis techniques are well established[25]. However, examining
the differences between the FTIR spectra has proven to be challenging due to the complexity of
the biological constituents, which have different vibrational modes[26, 27]. Therefore, in FTIR
studies, sophisticated spectral analysis techniques are employed to overcome these inherent
spectral interpretation challenges caused by highly overlapping absorbance peaks[26].
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A variety of choices are available for the sampling modes. The three major sampling modes
of FTIR spectroscopy include transmission, transflection and the attenuated total reflectance
(ATR). The spectra measured by FTIR are similar in each sampling mode, but subtle differences
exist in the interaction between light-matter interaction. The Figure 1.1 (B) shows the schematic
of light-matter interaction in each sampling mode; transmission, transflection, and ATR. In
transmission and transflection sampling mode samples can be sectioned into a thin layer, allowing
for accurate spectral data acquisition. For illustration, in transflection mode, the sample is placed
on IR-reflecting surface and measurement are performed. In this mode, the IR/source light passes
through the sample and will reflect back from the reflecting surface (substrate) through the
sample[24]. In transmission mode, incident infrared beam passes through the sample (prepared in
the form of pallet, mull films etc.) and the transmitted energy is measured to generate a spectrum.
Similarly, in the ATR sampling mode IR beam is directed through an internal reflection element
(IRE) of high refractive index[24].
1.1.1

Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR)
Spectroscopy

ATR-FTIR spectroscopy is an excellent analytical technique to understand the molecular
composition of soft biological mediums and complex body fluids. It provides a complementary
technique compared to other IR approaches [28, 29] for clinical diagnostics. Thus, it is an attractive
technique for the rapid and reliable extraction of the molecular composition within the diagnostic
medium[24]. Combined with appropriate data analysis, this technique has been applied in a few
biological studies as reported in a review article[23]. In ATR-FTIR spectroscopy, light is totally
reflected inside the prism of the high refractive index[28], and the reflected light from the sample
(Goos-Hanchen effect)[30] creates an evanescent wave, penetrating the sample placed in contact
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with crystal[31]. The energy of the evanescent wave first interacts with the sample medium, and
the incident wave is entirely reflected in the system as shown in figure 1.2 (A). The output spectra
represent a snapshot of molecular components within the sample medium. Herein, the penetration
depth (Figure 1.2 (B)) of evanescent energy waves, 𝑑𝑝 = 𝜆/2𝜋(𝑛1 2 𝑆𝑖𝑛2 𝜃 − 𝑛2 2 )

1⁄
2

depends on

the wavelength of incident radiation (𝜆), the refractive index of the crystal (𝑛1 ), the angle of
incidence (𝜃), and the refractive index of the sample (𝑛2 ). It is noted that the evanescent wave
decays exponentially in relation to the distance from the interface[32], so the penetration depth is
only a fraction of incident IR wavelength. The evanescent waves lose energy at frequencies
identical to the sample’s absorption because soft biological materials[33], such as the serum, make
intimate contact with the ATR element.

Figure 1.2 Interaction of light with sample in ATR sampling mode of FTIR
spectroscopy[11]. (A) Schematic diagram of the evanescent wave formed on the sample at the
internal reflection element surface. (B) Interaction of infrared signal in the material of the
medium.
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1.2

ATR-FTIR Spectroscopy of Serum Samples for IBD Studies

The two primary clinically identified IBDs; Ulcerative Colitis (UC) and Crohn’s disease
(CD), are debilitating, with a chronically inflamed gastrointestinal (GI) tract[34]. It can limit an
active lifestyle and lead towards the life-threatening complications[34], including secondary
infections, organ degeneration, nutritional deficiencies, and even GI cancer[35]. The incidence and
prevalence rates[36] of these diseases with unknown etiology have been increasing globally.
According to The Crohn’s and Colitis Foundation of America, approximately 1.6 million
Americans suffer from IBD, with 70,000 new cases being diagnosed every year [37].
Rapid detection and preventative interventions of these diseases enable the early
administration of therapeutic strategies when the treatment is most effective. Simultaneous
monitoring of mucosal healing during the treatment is also critical for IBD. Furthermore, IBDs are
chronic inflammatory disorders that affect the GI tract and are characterized by episodes of relapse
and remission requiring continuous monitoring. Certainly, ground-breaking advances in the
interruption of these diseases[38] have been achieved using human and animal models of intestinal
inflammation. However, a reliable screening test to diagnose these illnesses by primary care
physicians, and hence the early administration of the therapeutic strategies, is not yet available[39].
At present, the gold standard routine tests such as colonoscopy, sigmoidoscopy and small
bowel follow-through are recommended for colorectal and GI diseases[40], including IBDs. The
existing guidelines recommend that individuals, fifty to eighty years of age should get a
colonoscopy done every five years as part of a routine checkup[41]. Nonetheless, these goldstandard tests are expensive (requiring specialized instruments and qualified personnel and prior
preparation), invasive, risky (such as colonic perforation, hemorrhaging, post-polypectomy
electrocoagulation syndrome and infections), unpleasant for patients, and are not easily accessible
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to the eligible population for disease screening. These factors have become significant hindrances
to patient adherence to regular preventative IBD disease screening and monitoring. Studies further
show that the onset of IBD typically occurs in the second and third decades of life[42], progressing
into episodes of relapse and remission in the GI tract. Therefore, developing an affordable,
sensitive, specific, user-friendly, robust and rapid, equipment-free and deliverable to the end-users
(ASSURED) prescreening test before a colonoscopy is a critical need.
Blood and it’s component-based biomarkers[43] have been previously studied, utilizing
gene panels to predict and discriminate IBD disease activity[44]. The blood gene expression
analysis offers the significant potential to expand the understanding of the underlying genes’
involvement[44], and can play a major role in the development of personalized medicine[45]. Data
interpretation in gene expression analysis is not straightforward and requires several steps
appropriate to the experimental protocols[43-45]; thus, gene expression analysis is not yet able to
provide a low cost, quick and easier early screening test, keeping the traditional means of
evaluations (such as a colonoscopy) as the gold standard. We explore the utility of FTIR
spectroscopy of serum samples in ATR sampling mode[24], which could, in the future, allow
physicians to diagnose and/or monitor IBDs in its early stage. This technique is simple but
possesses the potential for radical change from standard practices as it will lead to the development
of a preventive screening technique before the use of invasive, risky colonoscopy.
The loss of energy in the decaying process will be at frequencies identical to the sample’s
absorption for soft biological materials like body fluids[33]. Similarly, metabolic discharges into
the body fluids (saliva, excreta, blood, and other tissue fluids) from the proximate diseased tissue
change the constituent molecules, providing strong guidance for subsequent clinical
assessment[33, 46]. Therefore, body fluids are considered as precious and ideal diagnostic
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mediums of clinical biomarkers owing to the advantages of minimal invasiveness, low cost, and
rapidity of sample collection and processing. ATR-FTIR spectroscopy of body fluids has garnered
much attention in the scientific community, including from clinicians[47, 48]. Serum is the
protein-rich blood component extracted after the removal of cells and clotting factors from the
whole blood sample[49] and it is used in numerous diagnostic tests[50, 51]. Thus, present infrared
spectral studies enriched with data analysis techniques on samples of human IBD patients and
experimental mice[4-10]can pave the way for identifying diseases in the blood.
1.2.1

Spectroscopy of Serum Samples from Experimental Mouse Models

Mouse models have been a vital tool for research in GI Diseases. The understanding of
intestinal inflammation in the IBD has been immeasurably advanced using several mouse models.
The study presented in this dissertation also demonstrates the applicability of ATR-FTIR
spectroscopy by analyzing biochemical changes in samples of IBD mice.
First, detailed insight into the molecular structural changes in serum samples of the DSS
induced colitis mice[5] is presented. The DSS mouse model provides us an inexpensive, simple,
and reproducible model to study human IBD. In addition to serum from DSS mice, this dissertation
reports the use of serum samples of IL10-/- deficient mice. Herein, mice with IL10-/- deficiency
treated with and without anti-TNFα antibody therapy was used to understand the efficacy of the
technique for drug signature monitoring[6]. IBD patients tend to have a low IL10-/- producer
genotype (a regular cytokine that plays a major role in the homeostasis of the gut) more often than
healthy controls[52, 53]. Therefore, genetically engineered IL10-/- deficient mice were most
frequently used as experimental models for chronic IBD studies. Longitudinal analysis of serum
samples of IL10-/- mice using two-dimensional differential gel electrophoresis (2D-DIGE)
proteomic analysis has shown that the accumulation of various proteins was altered under
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inflammatory conditions[54]. Importantly, a study has shown that this mouse model develops
spontaneous chronic IBD and are showing a promise as a model for adequately recapitulate the
full complexity of the human disease[54]. It has been found that, human IBD is a chronic intestinal
inflammation disorder with an unknown etiology. The genetic and epigenetic factors also play an
important role in the onset of disease and its progression[35]. Appropriateness of IL10-/- mouse
model to analyze the multifactorial nature of this disease including genetic factors, immune
aspects, and the role of the microbiota contributing to IBD is also reported[55]. Therefore, the
spectral signatures presented in this dissertation are common to both DSS and IL10-/- mouse[410]. The quantified information of Lipocalin 2 (Lcn-2) levels in feces of IL10-/- mice and
Myeloperoxidase (MPO) activity of distal colon in DSS induced colitis to monitor disease
progression are also used to evaluate disease level on each mouse[4, 5].
This dissertation also covers the efficacy of the FTIR technique to monitor anti-tumor
necrosis factor-alpha (anti-TNFα) antibody therapy in IL10-/- mouse[6]. IBD patients tend to have
an increased level of tumor necrosis factor (TNF) in serum, stool, or mucosal biopsy
specimens[56]. TNFα is a cell-signaling protein (cytokine) that plays a central role in
inflammation. Therefore, TNFα became a key target for antibody treatment for inflammation[55].
It is found that the diversity of fecal microbiota in the IBD patients shifts towards the control
individuals[57] after anti-TNF therapy. This treatment option leads to mucosal healing, reducing
hospitalizations, and surgeries while improving patients' quality of life[58]. Experiments on IL10/- deficient mouse models[59] also demonstrates the same outcomes[60]. The cytokines in the stool
samples show, the debilitating IBD conditions of IL10-/- deficient mice can be improved by antiTNFα antibody therapy[61].
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1.2.2

Spectroscopy of Serum Samples from Ulcerative Colitis (UC) Patients

The animal models are not enough for preclinical human disease studies and for confirming
the potential clinical applicability in humans. Therefore, as a follow-up step, we investigate a
diagnostic application of IR spectroscopy coupled with data analysis techniques to understand
ulcerative colitis-induced alterations in the molecular components of serum samples extracted
from IBD human patients. Alterations reflected as fluctuations in vibrational modes and are used
to identify suitable spectral signatures. The findings of this study resemble the proof-of-concept
investigation with experimental (both DSS and IL10-/-) mouse models, providing preliminary
evidence for a reliable diagnostic test for human ulcerative colitis.
This study enriched with data analysis techniques on human sera that resemble mouse study
can pave the way for identifying diseases in the blood while translating findings from an animal
study to a human study. The perspective of the technique with its appropriateness and necessary
improvements for the development of a new diagnostic regimen for IBDs using a serum is also
provided.
1.3

ATR-FTIR Spectroscopy of Serum Samples for Cancer Studies

The FTIR spectroscopy combined with appropriate data handling frameworks has been
widely applied in many oncological studies[23] such as studies using cancerous tissues from the
cervix[62], the lung[63], the breast[64], the skin[65], the gastro-intestine[66], the prostate[67], the
colon[68], the ovary[69], the urinary bladder[46]. These studies have reported that the molecular
structural rearrangement associated with cancer development alters the vibrational mode of the
molecular functional groups of the affected tissues as manifested in spectral signatures or
signatures. Furthermore, the ATR-FTIR[70] spectroscopy represents a complementary approach
for the clinical applications, compared to other IR approaches[29]. In this mode, high-quality
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results with better spectral reproducibility compared to other modes can be obtained by the use of
fluid samples[32]. It has been noted that metabolic discharges into the body fluids from the
cancerous tissue change the constituent molecules, providing strong guidance for subsequent
clinical assessment[33, 46].
1.3.1

Spectroscopy of Serum Samples from Mouse models of Lymphoma and
Melanoma

The incidence rates of cutaneous melanoma[71], a deadly form of skin cancer, has been
increasing in many regions and populations over the last few decades[72]. The increase has been
of the order of 3-7% per year among fair-skinned populations[73]. At the same time, nonHodgkin’s lymphoma (NHL)[74], a solid tumorous condition of the immune system with a wide
range of histological appearance and clinical features, accounts 4.3% of all new cancer cases in
the United States[75]. Although significant improvement has been made to stabilize the number
of NHL cases and to increase its five-year survival rate, the existing diagnostic techniques, which
include the histological examination using a biopsy, are time-consuming, invasive, costly, and are
not accessible to the entire at-risk population. Developing a rapid and reliable prescreening
strategy for melanoma and lymphoma is thus critical because of early diagnosis and treatment of
these malignancies better improve[76, 77] the patient’s chances of survival.
This study presents, ATR-FTIR spectroscopy of serum samples in an effort to assess
biochemical changes induced by non-Hodgkin’s lymphoma and subcutaneous melanoma[12]. An
EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneous melanoma
are used to extract a snapshot of tumor-associated alteration in the serum. The study of both cancerbearing mouse models in wild types and their corresponding control types, emphasizes the
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diagnostic potential of this approach as a screening technique for NHL and melanoma skin
cancer[12].
1.3.2

Spectroscopy of Serum Samples from Breast Cancer (BC) Patients

BC is the most common invasive cancer among women worldwide[78]. The international
agency for research on cancer (IARC) reports that BC comprises 22.9% of invasive cancers in
women[78, 79]. At present, personal inspection and imaging remain the preferred methods for
screening the asymptomatic women for BC. Nonetheless, the gold standard mammography entails
high costs, is not available in all medical centers, and has a low sensitivity in young women and
in the dense breast. Furthermore, BC typically produces less to no symptoms when the tumor is
small and is easily treatable[80]. Established mammography screening, may miss up to 20% of
underlying BCs [81]. It may also lead to a 30% rate of overdiagnosis and may increase unnecessary
surgical procedures and patient anxiety[82]. These limitations have led to the investigation of
blood associated protein markers[83] that can be used for BC screening before mammography.
The feasibility of markers like CA15-3, HSP90A and PAI-1 for the early prognosis[84] is still
unclear. It is thus critical to explore potential new markers that can help for early detection of BC.
Our study focuses on evaluating the feasibility of FTIR spectral discrimination of serum from
healthy controls and BC patients using protein conformational alteration in serum samples via
spectral deconvolution[13].
Moreover, the protein regulation[85], expression[86], and profiling[87] of tissues are
commonly used as indicators for the diagnosis, treatment, and prognosis of various stages of
BC[88]. FTIR spectrometry has also been successfully applied to commonly used diagnostic
material, such as blood components[88-91], breast tissue[92, 93], hair[94, 95], and other biological
samples[96], to discriminate BC samples[89-95]. Contrastingly, the applicability of the curve
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fitting technique while discriminating IR spectra of control and BC sera samples have not been
well understood[97]. Spectral fitting using characteristic Gaussian Function Energy Bands
(GFEB), improves the resolution and ease the inherent IR spectral analysis difficulties involving
highly overlapping absorbance peaks[25]. In fact, a key element appears to be missing; the details
of GFEB that have attributed to the specific functional groups present in sera and their BC induced
changes.
Additionally, body fluids, including blood-components, are considered as precious and
ideal diagnostic mediums of clinical biomarkers[98] owing to advantages of minimal invasiveness,
low cost, and rapidity for sample collection and their processing. The assessment of BC associated
changes in protein secondary structures of body fluids will thus be an emerging interest over the
existing histopathological examination of the breast biopsy materials. Alterations in the
biochemical composition of the serum could reflect changes of physiological states due to BC,
enabling early disease diagnosis and treatment[99].
1.4

Protein Conformational Studies using FTIR Spectroscopy

X-ray crystallography and nuclear magnetic resonance (NMR) have been widely used to
examine the structure of proteins and other biological macromolecules[100]. Despite the fact they
have been successfully used in biochemical studies over the years when it comes to the highresolution analysis of protein structure and function, the use of these complementary spectroscopic
methods is hindered by the need for sampling protocols[101] and sophisticated data analysis tools.
The X-ray diffraction technique requires a well-ordered crystal[101], while the use of NMR
spectroscopy is limited to small proteins[102]. Data analysis protocols for these techniques are
also complex, complicating the interpretation of the results. These limitations have led to the
development of alternative methods for determining protein structures.
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FTIR spectroscopy is one alternative method that can be used for protein secondary
structure analysis [4, 103, 104]. In previous reports, the FTIR spectroscopic investigation of
protein secondary structures[105] in BC patient serum samples was validated by several other
analytical techniques[106] such as X-ray, NMR[107] and Circular Dichroism spectra (CD)[108].
FTIR technique has also been tested with various sample types and conditions, including living
cells[109], aqueous media[110], Hydrogen deuteration[111] in serum[112], dehydration[113], and
heat-induced[114, 115] denaturation of serum. Additionally, spectral deconvolution[108] has been
employed to diagnose or monitor various ailments, including prostate cancer[116], lymphoma,
melanoma, Alzheimer’s disease[117], Parkinson’s disease[118], colitis, and scrapie[119].
Moreover, this method has been successfully used to study protein-protein interactions[120], the
structure of calcium-binding proteins[121], and the understanding of the uses and misuses of
techniques[122], their optimizations,[123] and instrumental improvisations[124]. Protein
structure, as well as protein conformational changes[125], structural dynamics, and stability, have
also been successfully determined using the second derivative curves[126]. All in all, FTIR
spectroscopy has emerged as a powerful tool to study protein secondary structures and can be
clinically useful in the early diagnosis of diseases.
In the present proof-of-concept pilot study, we have used the FTIR spectral discrimination
using curve fitting, to obtain the best fit that reflects protein conformational changes in serum
samples of BC patients. The curve fitting technique is also elaborated on the complex spectral
region of carbohydrates and nucleic acids, 1000-1140 cm-1 By deconvoluting these regions of
experimental spectra with the corresponding GFEB of various biological components, the
differentiating signatures of controls and cancerous spectra were determined. Other IR spectral
markers such as peak positions of the absorbance curves and spectral signatures such as the ratio
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of absorbance values in amide II to amide III bands are also considered for discrimination.
Statistical analysis is further performed in these identifying spectral signatures to understand
discriminating potential. Herein, the accepted scientific premise is that the BC associated genetic
alteration in serum is reflected in the complex region of nucleic acids including deoxyribonucleic
acids (DNA) and ribonucleic acids (RNA). Therefore, our discussion also includes the possible
application of genetic and proteomic molecular mapping in serum samples via FTIR spectroscopy
for early detection of BC. We have incorporated statistical measures, holistically evaluated the
biochemical mapping of protein structures and circulating nucleic acid components by using IR
spectral deconvolution. A unified fitting protocol for all the samples and a potential prototype
applicable in clinical domain is also presented. These findings go beyond the earlier study[97]
providing spectral signatures with higher sensitivities and specificity. Similarly, the
implementation of optimized experimental and data analysis protocols, and quantification of the
spectral signatures by scrutinizing molecular entities rather than relying entirely on wider spectral
ranges, are the improvements over an earlier study[89].
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2

EXPERIMENT

Sample handling and measurement methods were carried out in accordance with relevant
guidelines and regulations. The sera were thawed upon purchase/obtain and stored at -80oC until
analysis. Instrumentation, measurements and analysis follow the standard protocols[24, 25].
Herein,

the

selection

of

instruments,

their

measurement

parameters,

spectral

measurement/analyzing protocols, animal model selection, and human patients’ samples are
described in stepwise.
2.1

FTIR Spectrometer

All the IR spectral data were obtained with the use of a Bruker Vertex-70 FTIR
spectrometer fitted a KBr beam splitter and Deuterated Tri-Glycine Sulfate (DTGS) detector. An
MVP-Pro ATR accessory fitted with a diamond crystal configured to have a single reflection was
used. Medium Blackman-Harris apodization function was employed with a resolution of 4 cm-1
and a zero-filling factor of four to provide the best resolution ability (maximum signal-to-noise
ratio). The aperture size is also set to 2.5 mm for the optimization of the detector response without
saturation. A Parker-Ballston gas purging system was also used to maintain purified ambient air
in the spectrometer.
We have performed repeated measurements and extract information from several studies,
including references [23-25, 32], while selecting these parameters. This selection allows us to
reduce noise, and to analyze the spectral data without losing information during spectral
deconvolution. Resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1 resolution gives
rise to missing secondary structure information (spectral signatures show a lower degree of
variability), while using a diamond ATR crystal. Therefore, a resolution of 4 cm-1 with a zerofilling factor of 4 to give a data spacing of 1 cm-1. Diamond has a smaller acceptance angle cone,
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which allows having a good optical design to extract good spectra. Because of the strong robust,
and chemically inert feature of the diamond, it is considered as the best ATR crystal for routine
measurements of biological samples[127]. Thus, optimized values of measurement parameters are
used in this experimental and equipment setup.
2.2
2.2.1

Animal Growth and Sample Collection
Dextran Sodium Sulfate (DSS) Mouse

Three-week-old female C57BL/6 wild type (WT) mice were obtained from Jackson
Laboratories (Bar Harbor, ME). Mice were group-housed under controlled temperature (25°C) and
photoperiod (12:12-h light–dark cycle) and fed ad libitum. Animal experiments were approved by
the Institutional Animal Care and Use Committee of Georgia State University (Atlanta, GA), and
performed in accordance with the guide for the Care and Use of Laboratory Animals by U.S. Public
Health Service. All procedures were approved under the IACUC protocol #A14010.
C57BL/6 WT mice were administered DSS (MP Biomedicals, Solon, OH) at 3% in
drinking water ad libitum for 7 days. Feces and blood were collected on day 0 (before DSS
treatment) and day 7. Hemolysis-free serum was collected by centrifugation using serum separator
tubes. Mice were sacrificed by CO2 euthanasia.
2.2.2

Interleukin 10 Knockout (IL10-/-) Mouse

The IL10-/- mouse model develops IBD in a time-dependent manner[59]. Similarly, the
anti-TNFα treatment on IL10-/- mice show the therapeutic efficacy in resolving intestinal
inflammation[60]. A study indicates that IBD development and their healing is independent of sex
(male or female) in IL10-/- mouse[61]. Similarly, Anti-TNF drugs have proven highly effective
for targeting and diminishing the downstream effects of TNFα activation. However, the precise
mechanism is still unclear[128]. Studies have shown that a significant proportion of patients do
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not respond to the treatment, or they lose the effect over time. Therefore, 30-40 % of CD patients
and 25-30 % of UC patients still need surgery at some point during their life addition to the
biological treatment[129, 130].
In this study, eighteen, three weeks-old female (IL10-/-) knockouts mice, obtained from
Jackson Laboratories (Bar Harbor, ME), were used. Nine mice were treated with anti-TNFα
therapy, twice a week by intraperitoneal injection of anti-TNF antibody, starting from the 28th day
of their birth, and rest (n=9) are treated with Phosphate buffered saline (PBS). Feces collected on
day 28 (4 weeks) and day 98 (14 weeks), and Lipocalin-2 (Lcn-2) was measured to assess the
intestinal inflammation in those mice[131]. Total RNA was also extracted from colon tissues for
further analysis.
Similarly, blood samples collected on day 28 and day 98 was centrifuged by using serum
separator tubes for IR spectral measurements. Herein, samples collected from mice on day 28,
before they develop colitis constitute the control or non-colitis (n=16). The samples extracted on
days 98 of PBS injected mice are colitis (n=9). Similarly, the samples extracted on days 98 from
anti- TNFα injected colitis- mice are treated (n=9). All studies were performed following the
Institutional Animal Care and Use Committee at Georgia State University (Atlanta, GA), permit
number: A14010.
Herein, we have analyzed microRNAs (miRNAs) to analyze the efficacy of anti-TNF
treatment. It is noted that miRNAs are promising biomarkers for IBD[132]. We examined the
expression levels of pro-inflammatory cytokines in the colon, to understand the response of
therapeutics. Herein, the colonic miRNA expression analysis is performed by the quantitative
polymerase chain reaction (qPCR) by following the protocol as discussed[132].
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2.2.3

Collagen Antibody-Induced Arthritis Mouse

BALB/C WT mice received collagen antibody injections (200 µL) on day 0 by an
intravenous (tail vein) injection. (On day 6, mice received lipopolysaccharide (200 µL) by
intraperitoneal injection in order to boost the effect). Blood samples were collected from each
mouse on pre-treatment (day 2) and on post-treatment (day 12) from the jugular vein. Hemolysisfree serum was collected by centrifugation of the collected blood using serum separator tubes.
2.2.4

Toll-Like Receptor Knockout (TLR5-/-) Mouse Model of Metabolic Syndrome

TLR5-/-) mice were grown in our facility (Dr. Merlin’s lab at the Biology department).
TLR5-/- spontaneously develop metabolic syndrome as previously described[133]. Age-matched
wild type (WT) and TLR5-/- mice were fasted for 5-h and baseline blood glucose levels measured
with a blood glucose meter (Roche) using blood collected from the tail vein.
2.2.5

Human Sera of IBD Patients

Serum samples of IBD human patients were provided by Dr. Emilie Vienna’s from Dr.
Didier Merlin lab at the Institute for Biomedical Sciences, GSU, Atlanta, GA 30302, USA. These
human sera were obtained from Equitech-Bio, Inc. (Kerrville, TX, USA). Information about IBD
patients is provided below in Appendix A.4.
2.2.6

B16 Melanoma or EL4 Lymphoblast Tumor Model

C57BL/6J mice (6-8 weeks, 20-22 g, the Jackson Laboratory) were engrafted with B16
melanoma or EL4 lymphoblast via subcutaneous (s. c.) route with 2 x 105 of each cell line. B16
and EL4 cells were obtained from the American Type Culture Collection (ATCC) and maintained
in DMEM with 10% FBS prior to use. Mice were euthanized after 3 weeks of tumor inoculation
when tumors were larger than 1000 mm3 in size (see figure 1, inset (i)). Serum samples from
tumor-bearing mice and healthy mice were isolated and stored in -80oC until analysis. All
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experiments using animals described in this study were approved (protocol number: A17015) by
the Institutional Animal Care and Use Committee (IACUC) of Georgia State University, Atlanta,
GA, and experiments were conducted according to the guideline of Office of Laboratory Animal
Welfare (OLAW), Assurance number: D16-00527(A3914-01).
2.2.7

Human Sera of Breast Cancer (BC) Patients

Human sera from BC patients were obtained from the Breast Satellite Tissue Bank,
Winship Cancer Institute, Emory University, Atlanta GA, USA. The Helsinki Declaration
guidelines were followed for sample collection, and informed consent was obtained from all
patients. Blood was collected without additives from patients after informed consent. The blood
was then centrifuged at ~3200g for 10 minutes, and serum was pipetted and stored at -80oC until
analysis. The control healthy individual sera were from the baseline collection of healthy women
(age 41-58 years) participating in an independent intervention study under approval number 13317,
Edith Cowan University, Perth, Australia. All participants provided informed consent. The sera
were thawed, aliquoted in small volumes, and stored at -80oC until analysis. Information about the
BC patients is provided below in appendix.
In this study, the serum samples from healthy controls were provided by Dr. Marlena
Catherine Kruger at the Department of Nutritional Science, School of Food and Advanced
Technology, College of Sciences, Massey University, Tennent Drive, Palmerston North 4442,
New Zealand.
2.3

Spectral Response Measurements

The surface of ATR crystal was first cleaned with sterile phosphate-buffered saline and by
ethanol. The cleanliness test was then conducted to ensure there are no signal peaks higher than
the environmental noise level. Background measurement, showing the presence of any
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environmental residue on the crystal surface or in the light path, was performed on a clean surface
before each measurement. It allows us to get high-quality spectra using background corrections.
Serum samples (1 µL) are deposited in order to fully cover the crystal surface and allowed to air
dry (~10 minutes) at room temperature. An evanescent wave produced at the interface by the
internal reflection of light interacts with the layer of the sample within the penetration depth[134]
(see Appendix A.2 for detail). Each sample was scanned multiple times to get ten or more highquality (exactly overlapping) spectral data within the mid-infrared range 400 to 4000 cm-1 and 6
reads of the 100 co-added scans for each sample (total of 600 scans) were averaged. Using OPUS
6.5 software, all the spectra were min-max normalized by scaling the range 1800 to 900 cm-1. This
range comprises a significant biochemical fingerprint of the biological material and the amides (I
and II) bands[24]. Vector normalization[135] is another popular protocol where the average
absorbance is subtracted from each data point, and the spectrum is divided by the square root of
the sum of squares of absorbance. In general, the normalization protocol[24] can be chosen to best
serve the purpose of comparison. In this study, min-max normalization to the amide I peak is
employed as it emphasizes the deviation between the colitis and control sample spectra. Min-max
normalized spectra were then sectioned within the range of 1800 to 900 cm-1 for further analysis.
The vector normalization is also used while comparing the second derivatives spectra.
2.4
2.4.1

Data Analysis
Hierarchical Cluster Analysis (HCA) and Dendrogram Plot

Our analysis includes the dendrogram of HCA, which is commonly employed to identify the
similarities between the FTIR spectra by using the distances between frequencies and aggregation
algorithms [63]. Using the “PAST (Paleontological STatistics[136]) 4 - the Past of the Future”
software and the vector normalized second derivative curve of the absorbance spectra as input data
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(variables), HCA is performed and the dendrogram is plotted. Dendrogram tree diagram
performed, using Ward’s algorithm and Euclidian distance measurements, allow us to visualize
the overall classification.
2.4.2

Principal Component Analysis (PCA)

PCA, a useful statistical analysis[137], is first performed to explain the holistic evaluation
biomolecular content variations reflected in infrared absorbance data. Using the “PAST
(PAleontological STatistics) 4 - the Past of the Future” software and the vector normalized second
derivative curve of the absorbance spectra, as input data variables, we analyzed the variancecovariance matrix with the pairwise exclusion of missing values to get the component plots. The
scatter plot of PC1 and PC2 were used to visualize the clustering of groups together with different
magnitudes and directions. The scree plot is also used to check the total variance presented by PC1
and PC2 is significant. These findings from the PCA analysis led us to investigate spectral
signatures useful in the clinical domain.
2.4.3

Spectral Fitting (Deconvolution) for Protein Conformational Studies

We perform quantitative analysis of the absorption band values at different spectral
markers’ positions, which follows discrimination of secondary structures by deconvolution of the
spectra in the amide I region. During the deconvolution process, the computed curve that best fit
with the experimental spectrum is obtained from the superposition of Gaussian function energy
bands (GFEB). The individual bands from deconvolution represent proteins’ secondary structures
as discussed in the protocol papers, and similar studies in the field[108, 116-118, 120, 126] which
were used to verify the applicability of this technique over complementary spectroscopic methods
(X-ray crystallography, and nuclear magnetic resonance).
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Figure 2.1 The process of spectral deconvolution[6]. (A) Second derivative spectra of
amide I absorbance curve 1600-1700 cm-1. (B) Gaussian function energy bands used to obtain a
curve that fits the experimental absorption curve. (C) Second derivative spectra of nucleic acids
and carbohydrates, complex band 1000-1140 cm-1. (D) Deconvolution of the complex band by
estimating the number and position using the minima of the second derivative curve.

The process of deconvolution includes sectioning of min-max normalized spectra followed
by rubber-band correction with two baseline points, such that absorbance values at extreme ends
of the selected region will be zero. These spectra were then fitted with GFEBs by approximating
the position and the number of bands from the minima of second derivative spectra (Figure 2.1
(A)) and also by the minimization of root mean square error via the Levenberg-Marquardt[138]
algorithm. In the fitting process position, height, width, and hence integral varied such that the
simulated curve best fits the experimental curve. Herein, the goodness of the fit is determined by
the convergence of the root mean square error or the residual to a singular minimum value. Figure
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2.1 (B) shows the spectral fitting within amide I. Using six bands with corresponding biological
components; side chain, beta-sheet, alpha helix, disordered structure, and beta turns, we found that
fitting solution is unique as determined by the second derivative. The minima (position and
number) of the second derivatives of the spectral curves reflect the positions and the number of
bands needed to fit the spectral curve. The minor variation of the positions of the six bands are all
within the acceptable ranges for those biological components. Similarly, by choosing the number
and positions of bands indicated, excellent root mean square (RMS) error values less than 0.0035
were obtained. It further allows us to overcome the challenges[139] of deconvolution process for
quantitative analysis. Herein, by normalizing and sub-sectioning, the amide-I region of absorption
spectra followed by baseline correction and spectral fitting, the effects of the bands describing
individual biological components allow us for a more precise analysis of the spectra, thereby
increasing confidence while comparing two states.
Similarly, the complex region[140] of carbohydrates and nucleic acids 1140-1000 cm-1 is
deconvoluted with six GFEB, describing individual biological components is as shown in figure
2.1 (D). The number and positions of GFEBs are again approximated by using the minima of
second derivatives (figure 2.1 (C)). The sum of the integral areas covered by six bands was further
statistically analyzed.
2.4.4

Statistical Analysis

Quantified values of these identifying spectral signatures are statistically analyzed to see
the colitis-associated alteration in the blood serum, and their stabilization after biological therapy.
Our statistical analysis mainly includes finding the sensitivity and specificity of the signatures for
their discrimination. Sensitivity and Specificity of a diagnostic test are often used to describe the
diagnostic accuracy/performance of the analysis in biomedical research[141]. The discriminating
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potential of a diagnostic regimen can be quantified by the Youden index and the area under the
receiver operating characteristic (ROC) curves [142]. The ROC curve is plotted to find the area
under curve (AUC). The optimal cutoff value calculated based on the Youden index for each
spectral marker is used to select the positivity/negativity of the disease and to estimate the
sensitivity and specificity.
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3

RESULTS

The result section systematically explains the identifying spectral signatures in mouse
models and human patients in a stepwise pattern. The quantitative information reflected in
identifying spectral signatures; are further analyzed by using statistical analysis techniques.
3.1

Identifying Infrared Spectral Signatures of IBD in Serum

The serum sample extracted from the experimental models of IBD: IL10-/- and DSS mouse
shows diagnostic accuracy with 80-100% sensitivity and specificity values. Importantly, the
findings of human IBD patients’ study also resemble these proofs-of-concept investigations using
mouse serum. Maximum values of sensitivity and specificity are 100% and 86%, respectively, in
human samples.
3.1.1

Spectral Signatures in Serum of DSS Mouse

The encouraging results of the earlier studies using DSS mouse[4, 5] have motivated us
further elaboration by monitoring the temporal variation of molecular composition in the serum
along with the colitis aggravation[11]. We examined samples at days 0, 3, and 7 of the chemical
feeding. Six mice (S1, S2, S3, S4, S5, and S6) were fed 3% DSS dissolved in drinking water. The
serum samples were tested for the disease progression using the spectral response analysis. After
analyzing the absorbance spectra within spectral range 1000-1140 cm-1, we learned the
concentration of carbohydrates such as glucose and mannoses was elevated due to colitis as judged
in previous studies[4, 5]. These studies have shown that the elevation of the spectral band
representing the Mannose presence in the carbohydrate region. Similarly, increased presence of βpleated sheet protein secondary structures and decreased the presence of α-helical structures in the
Amide I region (1600-1700 cm-1) is also evaluated.
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Figure 3.1 (A) shows the average (n=6) of max-min normalized spectra of mice sera
extracted from three different time periods before (days 0, 3, and 7 of chemical feedings) the DSS
mouse model, with a Biomolecular assignment at different wavenumber regions. Our study is
primarily focused on testing the temporal variation in serum components along with the colitis
progression by analyzing identified unique spectral signatures of colitis (shaded regions in figure
3.1). The second derivative curve of the absorbance spectra is shown in figure 3.1(B). Visual
inspection of each type of spectrum shows the alteration of disease Biomarkers due to colitis. This
variation can be seen on day 7 of DSS feeding, but not on day 3.

Figure 3.1 (A) Averaged (n=6) ATR-FTIR spectra of serum samples derived from DSS
mice on day 0, day 3, and day 7 of the chemical feeding. The variation in infrared absorbance on
day 7 is higher in the complex region of carbohydrates and nucleic acids compared to on day 3.
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(B) Second derivative curves of the absorbance spectra. Second derivative spectra show the
variation on day 7 in the amide I region. Herein, shaded regions show two major regions of
interest[11].

Figure 3.2 Longitudinal analysis of serum samples of DSS induced colitis mice[11]. (A)
Normalized absorbance values in the range 1000-1140 cm-1 showing changes in spectral
signatures representing carbohydrates and nucleic acids are significant at day 7, but not at day 3.
(B) The integral ratio of Gaussian function energy bands representing α-helix and β-sheet
secondary structures of proteins in serum samples extracted from six mice (S1, S2, S3, S4, S5 and
S6). The secondary structure analysis also shows the significant changes only at Day 7.
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Figure 3. 2 (A) shows the normalized absorbance spectra covering the complex region of
carbohydrates and nucleic acids (1000-1140 cm-1). IR absorbance values of this region are more
on day 7, where mice develop fully colitis. In the normalized data, absorbance values of the
spectral position, 1076 cm-1 representing mannose, for the control (day 0) are between 0.44-0.47
a.u., colitis (day 7) are 0.49-0.53 a.u. that the values for the intermediate (day 3) stage lies within
the range of control. Similarly, the ratio of the integral areas taken by GFEBs representing α-helical
and β-pleated sheet protein secondary structures for each individual mouse is shown in figure 3.2
(B). The integral ratio of α-helix and β-sheet protein structures also show a clear difference in the
spectral data representing day 0 with those representing day 7 of chemical administration, while
there is no significant difference in day 3 data. In these two regions of interests (first: Glucose,
Fructose, Mannose, and Endocyclic C-O-C vibration and second: α-helical protein secondary
structure of amide I and β-pleated sheet structures) show alteration with higher statistical
significance (student’s t-test, two-tailed unequal variance p-value < 0.05).
3.1.2

Spectral Signatures in Serum of IL10-/- Mouse

This study is the follow up for an earlier study from our lab[5]. Addition to earlier studies,
we have increased the number of mice (samples) and therapeutic effect of anti-TNFα is also
evaluated[6].
Discrimination of Absorbance Values: To monitor the therapeutic response of colitis,
we examine the chemical composition of serum samples derived from normal (n=16), IL10-/induced colitis (n=9) and with anti-TNFα therapy IL10-/- mice (n=9). Figure 3.3 (A) shows
average representations of the normalized absorption spectra of serum samples derived from each
mice type. Herein, we have monitored previously identified IR spectral signatures for colitis in
diseased species with anti-TNFα antibody therapy, which displays exciting results. The alteration
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in the IR absorption values (at identifying spectral signatures) due to colitis in IL10-/- mice come
close to control mice in the anti-TNFα treatment treated cases.

Figure 3.3 Normalized absorbance curve and p-value calculation results[6]. (A) Averaged
ATR-FTIR spectra of serum samples, derived from control (Non-Colitis, n=16), treated with antiTNFα antibody (Treated, n=9) and colitis untreated (Colitis, n=9) mice. These spectra show
proper anti-TNFα therapy ameliorate the colitis condition. Inset shows magnification within 12001000 cm-1 and 1660-1625 cm-1, which clearly shows how the absorbance curve of anti-TNFα
treatment comes close to the control levels. (B) P-value calculation of colitis and treated
conditions with control types. The p-value is less than 0.05 at various spectral bands while
comparing non-colitis and colitis, but it is always greater than 0.05 while comparing non-colitis
and treated. The region highlighted by the pink box is the region with p ≤ 0.05.
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The student t-test p-values on absorption spectra representing normal, colitis, and antibodytreated colitis mice are as given in Figure 3.3 (B). It shows how absorption values vary with control
Vs treated and the control Vs colitis within the entire wavelength region 900-1800 cm 1.
Throughout the whole wavelength region, the differentiating signatures better than 95% (or higher)
are highlighted by the shadowed area. These spectral regions with biomolecular assignments and
bond vibrations having a significantly better than 0.05 are assigned as C=O of lipids (1766-1780
cm-1), amide I of proteins (1670-1710 cm-1), amide I and amide II of proteins (1548-1649 cm-1),
CH3/CH2 bending (1317-1383 cm-1) and asymmetric PO2 stretching of phosphate lipids 1208-1244
cm-1, and the mixed region of carbohydrates, and nucleic acids in 900-1159 cm-1. Due to the
complexity of biological systems, biomolecular and bonding vibration assignments are tentative
and are based on numerous studies as shown in table 3.1. The colitis associated changes in all these
spectral bands come to the level of control in anti-TNFα antibody therapy mouse serum.

Table 3.1 Discriminatory Infrared spectral bands of UC, with biomolecular assignments
and their bond vibrations[6].
Band (cm-1)

Assignment and vibrations

900-1158

Carbohydrates[143, 144] (Glucose, Mannose, Fructose) and nucleic acids
(Deoxyribose/Ribose DNA, RNA)[145]: C-O, C-C stretch, C-H bends,
Endocyclic C-O-C vibration and, νs(PO2−)[146]

1208-1244

Amide III, νas(PO2−)[147]

1317-1382

Collagen: CH2 wagging, the vibration of α, and β anamor[148].

1420-1430

Polysaccharides, νs (COO-), 𝛅(CH2)

1480-1580

Amide II of proteins: (α-helical, β-pleated sheet, unordered conformation
structures), δ(N-H), ν(C-N)[25].

1600-1700

Amide I of proteins: (α-helical, β-pleated sheet, β-turns, random coils, and sidechain, β (anti-‖+turn) structures), ν(C=O), ν(C-N), CNN[25].

1720-1750

Lipids C=O stretching [149]
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Identified spectral signatures: In this study, identified spectra signatures are: (a)
absorption values at wavenumber 1033 cm-1 (I1033), primarily due to glucose presence; (b)
absorption values at wavenumber 1076 cm-1 (I1076), representing the mannose as well as
phosphate[23] presence; (c) the ratio of absorbance at wavenumber 1121 cm-1, associated with
RNA presence, to its value at 1020 cm-1, associated with DNA presence (I1121/I1020); (d) the ratio
of absorbance at wavenumber 1629 cm-1, indicating the protein presence, to 1737 cm-1 signaling
the presence of lipids (I1629/I1737); (e) the ratio of Gaussian function energy bands representing α
helix and β sheet protein secondary structures as obtained from the deconvolution of amide I
region; and (f) the sum of the integral area of GFEBs used to fit the experimental curve within the
complex band of carbohydrates, and nucleic acids 1000-1140 cm-1.
Earlier, various serological markers were analyzed for IBD diagnosis[43] and
discrimination of IBD types[150]. These studies have reported abnormalities in lipids, amino acids,
and energy metabolisms in the serum samples of IBD patients[151]. Associations between fatty
acids and inflammatory cytokines or the protein abundance and the epigenetic alteration in the
samples of IBD patients have been also established[152].
Similarly, proteomic analysis in serum samples of IL10-/- mice shows alterations of
various proteins[54] under inflammatory conditions. The protein secondary structure alterations
could be due to a melded manifestation of these protein variations. As such, variations in these
reported serological markers are most likely the primary reason for the IBD induced changes in
absorption frequencies of functional groups of proteins, carbohydrates, nucleic acids, and lipids.
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Figure 3.4 Representation of identifying spectral signatures[6]. (A) Ensemble average
representative of absorbance at wavenumber position 1033 cm-1. (B) Ensemble average
representative of absorbance at wavenumber position 1076 cm-1. (C) The ratio of absorption
values at wavenumber 1121 cm-1 to 1020 cm-1. (D) The ratio of absorbance at wavenumber 1629
cm-1 to 1737 cm-1. (E) The integral values of Gaussian function energy bands representing the α
helical structure of protein secondary structure. (F) The integral values of Gaussian function
energy bands representing the β pleated sheet structure of protein secondary structure. (G) The
integral ratio of α-helix and β-sheet protein secondary structures. It shows the increased level of
β sheet structures and a decrease in α helix structures due to colitis and their resettlement in antiTNF α therapy mice. (H) The sum of the integral area of GFEBs used to fit the experimental curve
in the complex band 1000-1140 cm-1.
The representation of ensemble averages for identifying five spectral signatures, I1033, I1076,
I1121/I1020, I1629/I1737, integral ratio (α/β), and the sum of the area of GFEBs used to fit 1000-1140
cm-1 are shown in Figure 3.4. Absorption values representing the glucose peak position at 1033
cm-1 is shown in figure 3.4 (A), and this value at the mannose peak position 1076 cm-1 is shown in
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figure 3.4 (B). The average ratio of the RNA peak to DNA peak (I1121/I1020) is as indicated in figure
3.4 (C), and the average ratio of the peak representing protein to lipid peak is shown in figure 3.4
(D). Figure 3.4 (E) and figure 3.4 (F) shows the integral values of the α-helix and β-sheet protein
secondary structures, respectively. Similarly, the average integral ratio of α-helix to the β-sheet
structure is shown in figure 3.4 (G). The sum of integral values of Gaussian bands used to fit the
experimental curve within 1000-1140 cm-1 are shown in figure 3.4 (H). These absorption and ratio
values are also tabulated in Table 3.2.
Although, the precise mechanism of anti-TNFα treatment in IL10-/- mice that helps to
regain altered biomolecules into the control level is still unknown[128]. Specifically, proteomic
marker (α/β) could be due to either due to anti-TNF alpha or due to the downstream expression of
other proteins. However, our experimental demonstration verifies the efficacy of IR spectroscopy
to monitor the signature of anti-TNFα therapy for inflammatory bowel diseases. Since the focus
of this work is to identify the IR signatures, regaining of altered spectral signatures of IBD close
to the control level in anti-TNFα treatment is an important finding.

Table 3.2 Quantified values of identifying spectral signatures: I1033, I1076, I1121/I1020,
I1629/I1737, integral ratio (α/β), and the sum of the integral area of GFEBs used to fit the
experimental complex band 1000-1140 cm-1[6]. Tabulated p-values represent a comparison
between control and colitis.
Features
Control
Colitis
Treated
P-value

Glucose
(1033 cm-1)
0.36 ± 0.01
0.41 ± 0.01
0.36 ± 0.01
1.3E-03

Mannose
(1076cm-1)
0.42± 0.01
0.46± 0.01
0.42± 0.01
2.9E-03

RNA/DNA
(1121/1020)
1.29±0.02
1.19±0.01
1.29±0.02
4E-04

Protein/Lipid
(1629/1737)
31.54±0.69
33.85±0.69
32.98±0.73
0.04

Integral
Ratio (α/β)
4.34±0.09
4.40±0.06
3.49±0.14
1.9E-05

Integral sum
Complex
13.04±0.16
14.17±0.12
13.0±0.18
2.1E-05

36
Statistical Analysis: The heterogeneity between each study type is further tested by using
quantitative analysis that involves the calculation of Youden’s index, the area under the receiver
operating characteristic (ROC) curves, sensitivity, specificity, and the calculated p-value [142].
Statistical measures[141] of these discrimination techniques also reveal the feasibility of the
studied monitoring regimen in the clinical domain. The ROC curves are plotted to find the area
under the curve (AUC); for each of these features, the threshold values were used to estimate the
sensitivity and specificity. Then, the Youden index, (the maximum of sensitivity + specificity –
1), was used to find the optimal cutoff values among the threshold values. Herein, figure 3.5 (A)
shows the confirmation of the effect of anti-TNFα therapy in studying mouse groups evaluated by
analyzing expression levels of TNFα in the total RNAs extracted from colons. ROC plots for the
(α/β) signature are shown in figure 3.5 (B).

Figure 3.5 (A) The expression levels of TNFα in the Total RNAs extracted from colons.
The level of TNFα is quantified by qPCR and it confirms the effect of anti-TNFα therapy. (B) ROC
curve for the data obtained from the ratio of the integral area of energy bands representing αhelix and β-sheet protein secondary structures. AUC is 0.95 while comparing colitis and non-
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colitis, but its value is 0.46 while comparing non-colitis and the treated. High diagnostic accuracy
(with AUC = 0.95) can be seen for colitis, but poor diagnostic accuracy (with AUC =0.46) for the
treated[6].

The maximum sensitivity and specificity of this particular signature were found to be 100%
and 81%, respectively. Sensitivity and specificity are major concerns in such studies and analysis
led to the identification of statistically significant differences in IR spectral markers between noncolitis, IL10-/- induced colitis, and with anti-TNFα treated mice experiments. Sensitivity,
specificity, and AUC values are calculated for all the identifying spectral signatures as shown in
table 3.3. Statistically, significant differences can be seen between non-colitis and colitis
conditions for identifying signatures. However, while comparing control and the treated
conditions, approximately 50% (0.5) AUC values can be obtained, showing there is not statistically
difference between control and treated groups.

Table 3. 3 Sensitivity, specificity and AUC value calculations of identifying spectral
signatures of UC in IL10-/- mouse[6].

Specifications
Sensitivity
Specificity
AUC (control
& colitis)
AUC (control
and treated)

Signatures
Glucose
Mannose
RNA/DNA Protein/Lipid
(1033 cm-1) (1076 cm-1) (1121/1020) (1629/1737)
89
89
100
90
88
88
75
56

Integral
Ratio (α/β)
100
81

Integral sum
complex band
100
75

0.88

0.86

0.90

0.73

0.95

0.92

0.54

0.56

0.49

0.66

0.46

0.55
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As seen in table 3.3, AUC values while comparing control and treated are 0.54, 0.56, 0.49,
0.66, 0.46 and 0.55 for the spectral signatures: I1033, I1076, I1121/I1020, I1629/I1737, integral ratio (α/β),
and the integral sum, respectively. Since the AUC values of colitis and non-colitis are higher (close
to 90%) and that of non-colitis and treated is close to 50%, showing these spectral signatures can
be applied to drug signature monitoring. Having shown the discriminating potential of the present
diagnostic regimen; it is essential to study many samples producing acceptable sensitivity and
specificity values. Discriminating temporal variation during disease progression or its suppression
is also a critical follow-up step.
The present study provides a detailed insight into the molecular structural changes in serum
samples of the IL10-/- IBD mouse model. Infrared spectral signatures representing proteins,
carbohydrates, nucleic acids, and lipids are identified as the potential signatures reflecting
molecular changes. The success of the present technique in measuring the effect of anti-TNFα on
the identified spectral signatures will provide an additional level of information about the treatment
option of IBD patients and will increase the possibility of adapting this technique for disease status
monitoring. Addressing the cost and hassle of colonoscopy that discourages people from being
screened timely, doctors, particularly primary care physicians can make their patients more aware
of IR spectroscopic analysis of blood serum. If the test shows an indication of diseases,
colonoscopy can be performed. However, at its present form, the molecular mapping in serum
samples as the IR signatures of the disease cannot replace gold standard colonoscopy tests but will
provide additional information about the IBD patients before colonoscopy. Therefore, the
feasibility of FTIR spectroscopy to extract a snapshot of cumulative molecular interactions within
mouse serum samples for IBD study warrant a thorough investigation, as enabled by
interdisciplinary collaborations between spectroscopists, biologists, and clinicians.
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Using a statistically significant number of experimental mouse models with different stages
of disease progression and healing can establish an association between identifying spectral
signature changes with the disease stage. Mouse model study helps us to establish an association
between spectral signatures of IBDs with histological findings of intestinal tissues. Understanding
the association between identifying spectral signatures and the abolition or restoration of tissue
functions in the intestinal tract is important because lymphocytes infiltrations and erosion of crypt
can be seen in the diseased IL10-/- mice.
Additionally, by building a logistic regression model for the spectral features and doing
cross-validation, a correlation between the degree of variation in spectral signatures and the level
of Lcn-2 in their stool or myeloperoxidase (MPO) activity of the distal colon can be established.
Research into samples of mice with intermediate stages of the disease will provide more insights
into the evolution of healing and add confidence to the analysis and the applicability of the
technique for early diagnostics. However, the animal models are not enough for preclinical human
disease studies and for confirming the potential clinical effects in humans. Therefore, a follow-up
step would be to analyze a statistically significant number of human samples to examine covariate
effects of demographic and clinicopathological variables like age, weight, ethnicity, diet, disease
stage, and comorbidities on the spectral signatures.
3.1.3

Spectral Signatures in Serum of Human Colitis Patients

Discriminate Control and UC Sera Using Absorbance values: Figure. 3.6 (A) shows a
typical min-max normalized[24] spectrum covering the fingerprint region for biomolecules
comprised of various biological functional groups of lipids, proteins, nucleic acids, and
carbohydrates. The spectral difference (UC-Control), as shown in the solid green line (▬) of
Figure. 3.6 (B), is significantly higher than the difference obtained from the multiple
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measurements of the same sample for both Control (▬ ▬) dashed and UC (••••) dotted lines,
almost completely overlapping). Figure. 3.6(C) shows the p-values of the Student’s two-sample ttest (with two-tailed unequal variance) for the absorbance representing 28 healthy volunteers
(controls) and 18 UC patients. P-values less than the nominal significance level of 0.05 indicate
the most discriminatory features of the spectrum. P-values less than 0.025 show the validity of all
the features, except for regions of lipid (pink line ▬ ▬).
The prominent, discriminatory regions include C=O/C-N stretching and N-H bends in
amides, C=O in stretching lipids, RNA/DNA nucleotides and C-O vibrations of
carbohydrates[153]. Because of the complexity of biological systems, biomolecular and bonding
vibration assignments are tentative and are based on numerous studies[23, 25, 147, 154-156]. The
spectral region, 1700-1750 cm-1, is primarily recognized by its C=O stretching band in lipids[23,
147]. The amide I (1600-1700 cm-1) vibration is known to be sensitive to the secondary structure
of proteins[25], which mainly arises due to C=O stretching vibration with minor contributions
from out-of-phase C-H stretching vibrations, C-C-N deformation and N-H in-plane bends. Spectral
band around 1578 cm-1 is due to C=N adenine[147] while the region 1136-1153 cm-1 is due to the
ring vibration mode of C-O-C including C-O-H, C-O and C-C stretch[154]. The spectral band 9001091 cm-1 results from C-O, C-C stretch, C-H bend, deoxyribose/ribose DNA, RNA, is(PO2−)
[154] of carbohydrates and nucleic acids.
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Figure 3.6 Infrared absorption spectra of sera to discriminate control and UC conditions.
(A) Ensemble average representative of min-max normalized absorbance spectra of 28 control
serum samples (healthy volunteers) and 18 UC patients indicating biomolecular assignments. (B)
The spectral response difference between UC and control. The average absorbance values of UC
conditions are elevated at carbohydrate and nucleic acids regions and fluctuating up and down in
the Amides region. The difference between repeat measurements of the same sample (Multiple
Controls and Multiple UCs) shown by the (▬ ▬ the blue dashed and •••• the red dotted lines
respectively) lines are negligible compared to the difference spectra between the average UC and
average control (▬ green; UC-Control). (C) p-values of the Student’s t-test (with two-tailed
unequal variance) for the absorbance representing healthy volunteers and UC patients. p-values
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less than 0.05 are used to the highlight strongest discriminatory features of the spectrum. p-values
less than 0.025 (horizontal ▬ ▬ pink-dotted line) show the validity of all the features except lipids.

Studies have investigated various serological markers[43] for UC diagnosis and the
discrimination between UC types with their clinical feasibility[150]. These studies have reported
abnormalities in lipids, amino acids, and energy metabolisms in the serum samples of IBD
patients[151]. Associations[152] between fatty acids and inflammatory cytokines or the protein
abundance and the epigenetic alteration in the samples of UC patients have been established. As
such, variations in these reported serological markers are most likely the primary reason for the
UC induced changes in absorption frequencies of functional groups of lipids, proteins, nucleic
acids and carbohydrates.
Protein Secondary Structure Analysis Via Spectral Deconvolution: The amide I
band[25], 1600-1700 cm-1, has been used for the analysis of protein secondary structures,
especially to observe their alteration due to changes in health conditions. We have also
implemented a spectral deconvolution technique within the amide I band to find the protein
secondary structure alteration in sera due to UC. The spectral band 1600-1700 cm-1 is deconvoluted
into six Gaussian band energy profiles representing the side chain (~1610 cm-1), β-sheet (~1630
cm-1), random coil (~1645 cm-1), α-helix (~1652 cm-1), β-turn (~1682 cm-1), and β-sheet antiparallel (~1690 cm-1) structures. Herein, the minima of the second derivative spectra are used to
find the position and the number of Gaussian function energy bands enough to fit the experimental
absorption curve. The integral area covered by energy bands representing the α-helix and β-sheet
is larger compared to other structures: side chain, antiparallel beta-sheet, disordered structure, and
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beta turns. In addition, the UC-associated alteration in the integral bands is also significantly larger
in the α-helix and β-sheet structures, hence only these two structures will be analyzed.

Figure 3.7 Plots of integral values of Gaussian function energy bands representing α-helix,
β-sheet protein secondary structures in human sera. (A) Quantified integral values of α-helix
components. (B) The integral values of β-sheet components. (C) Ensemble average representation
of integral values of α-helix. P-values for the integral area of α-helix is 0.05 and for the mean
position is 0.03. (D) Ensemble average representation of integral values of the β-sheet. P-values
for the integral area of β-sheet is 9E-07 and mean position is 0.3. (E) Representation of integral
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ratios between corresponding α-helix and β-sheet structures. Average values of control and UC
cases for the integral ratio of α-helix to β-sheet (Integral (α/β)) shows a statistically significant
difference with a p-value of 1E-04. (F) The ROC curve of the Integral (α/β) and the corresponding
AUC.

Figure. 3.7 shows a plot of the integral values of Gaussian energy bands representing the
α-helix and β-sheet protein secondary structures. The integral values of the α-helix components
are less for UC cases compared with controls (Figure. 3.7 (A)), while the integral values of the βsheet components are higher in UC cases compared with controls (Figure. 3.7 (B)). A significant
difference between the integral ratios of the α-helix and β-sheet structures can be obtained between
the control and UC groups in this study (Figure. 3.7 (C)). The mean wavenumber position, 1650.81
± 0.07, of the energy band representing the α-helix structure has significantly moved towards the
higher wavenumber position, 1651.05 ± 0.32 (with a p-value = 0.03), as shown in Table 3.5.
Similarly, the integral area covered by the energy-band representing the β-sheet structures are
different (p-value = 9E-07) between the control (19.05 ± 0.15) and UC (20.40 ± 0.17).
Table 3.4 Quantified information about average integral values and average position of αhelix and β-sheet secondary structure, energy bands in human serum samples.
Features

Types

α-helix

Control
UC
Control
UC

β-sheet

Integral
± std. error
42.74±0.25
41.94±0.08
19.05±0.15
20.40±0.17

Significance
(p-values)
No (> 0.05)
Yes (< 0.03)

Wavenumber
± std. error
1650.81±0.07
1651.05±0.32
1629.94±0.11
1630.12±0.11

Significance
(p-values)
Yes (< 9E07)
No (> 0.3)

Identified Spectral Signatures: Identified spectral signatures in this study are I1033, I1076,
I1121/I1020, I1629/I1737, and α/β secondary structure analysis. Histogram representation of ensemble
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averages for four spectral signatures, I1033, I1076, I1121/I1020, and I1629/I1737, are shown in Figure. 3.8
(A), 3.8 (B), 3.8 (C) and 3.8 (D), respectively.

Figure 3.8 Histogram representation of identifying spectral signatures. (A) Ensemble
average representative of absorbance of wavenumber position 1033 cm 1. (B) Ensemble average
representative of absorbance of wavenumber position 1076 cm-1. (C) The ratio of absorbance
values (I1121/I1020) at wavenumber 1121 cm-1 to 1020 cm-1. (D) The ratio of absorbances (I1629/I1737)
at wavenumber 1629 cm-1 to 1737 cm-1.

The altered pattern between UC and control groups can be seen by comparing the range of
data points and their average values in the identified spectral signatures as tabulated with standard
error in the unshaded region of table 3.6. The average absorbance value of the glucose peak for
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control and UC is 0.274±0.004 and 0.303±0.007 and the average for the mannose peak (for control
and UC) are 0.349±0.004 and 0.373±0.006, respectively. Similarly, the average ratio of the RNA
peak to the DNA peak is 1.510±0.011 (control) and 1.362±0.015 (UC), the average ratio of the
peak representing protein to lipid peak is 28.804±0.642 (control) and 33.373±1.519 (UC) and the
average integral ratio of α-helix to β-sheet structure is 2.250±0.030 (control) and 2.061±0.033
(UC).
Sensitivity and Specificity: The discriminating potential of any diagnostic technique is
further evaluated by sensitivity, specificity, ROC, AUC. Figure 3.7 (F) shows the ROC curve of
the integral ratio (α/β) and the corresponding AUC. Similarly, for each feature (Table 3.6) optimal
cutoff values, AUC values, sensitivity and specificity were calculated with the aid of ROC curves.
Quantified information about these features for corresponding spectral signatures are shown in the
shaded region in Table 3.6. The maximum values of sensitivity and specificity values of each
feature describe the differences between the UC versus the control groups.
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Table 3.5 Quantified information about identifying discriminatory bands. These include
absorbance values at 1033 cm-1 and 1076 cm-1, the ratios of absorbance at 1121 cm-1 to 1020 cm1

, 1629 cm-1 to 1737 cm-1. The integral ratios of Gaussian function energy bands representing α-

helix and β-sheet protein secondary structures are also discussed. Statistical measures of
discriminatory infrared spectral signatures for UC using sera shown in the shadowed region of
the table. The optimal cut-off and the corresponding sensitivity and specificity are calculated
based on the Youden index. P-values are calculated based on the student’s t-test with a two-tailed
unequal variance.
I1033
0.2440.328
0.274±
0.004
0.2570.375
0.303±
0.007
0.273289

I1076
0.3250.405
0.349±
0.004
0.3290.416
0.373±
0.006
0.351057

I1121/I1020
1.4821.611
1.510±
0.011
1.2311.444
1.362±
0.015
1.44565

I1629/I1737
21.12434.066
28.804±
0.642
22.26148.055
33.373±
1.519
32.8145

Integral(α/β)
1.9732.547
2.250±
0.030
1.8962.469
2.061±
0.033
2.09855

AUC

0.7817

0.7619

0.9444

0.7619

0.8313

Sensitivity (%)

89

78

100

61

78

Specificity (%)

68

68

86

93

82

p-value

0.001

0.003

2E-10

0.003

0.0001

Control

Types
Range
Average
± std. error
Range

UC

Average
± std. error
Cut-off value

3.2

Spectral Signatures of Lymphoma and Melanoma in Serum Samples of Mouse
Models

Discrimination of Absorbance Values:

Figure 3.9 (a) shows the average normalized

ATR-FTIR spectrum of air-dried serum samples extracted from tumor-bearing mouse models of
EL4 lymphoma (n=8) and B16 melanoma (n=8) in wild types and corresponding control types
(n=15). Using the student’s t-test, p-values (two-tailed unequal variance), the most discriminatory
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features of the spectrum within the spectral range 1800-900 cm-1, were extracted (figure 1(b)).
Interestingly, the features observed for different groups enable the classification between control
cases and malignant cases and between the two malignant cases of lymphoma and melanoma.
Molecular assignments[33, 157-161] of five spectral bands showing discrimination of EL4
lymphoma from their control types, with higher significance (i.e. p-values < 0.05) are presented in
Table 1. These are the bands originating from (i) amide I of protein, (ii) amide II of protein (iii) CH deformation of CH3/CH2 groups, (iv) asymmetric phosphate I, and (v) Carbohydrates and nucleic
acids. Similarly, two spectral bands showing the significant difference between B16 melanoma and
their control types are also shown in the shaded regions of the table. Significant alteration in the
amide I band, and the complex band of carbohydrate and the nucleic acids are observed for B16
melanoma. The difference in the p-values observed between lymphoma and melanoma could be
attributed to the difference in mechanism of each type of tumor development, while similarity could
be attributed to common etiology[162].

49

Figure 3.9 The discriminatory region of infrared absorbance spectra. (a) Average
normalized ATR-FTIR spectra of serum samples extracted from EL4-lymphoma (n=8), B16melanoma (n=8) mouse models in wild types and corresponding control types (n=15). The inset
(i) shows B16-melanoma mouse with tumor size approximately 1000 mm3 (day 18). An increase in
volume of the tumor from day 9 to day 18 of tumor inoculation in B16-melanoma mouse is as in
inset (ii). Like the B16 mouse, the elevation of tumor size is also monitored in EL4-lymphoma. The
serum sample is extracted for both types of mice when tumor size becomes bigger than 1000 mm3.
(b) Student’s t-test (two-tailed unequal variance) p-values of absorbance. Discriminatory region
for lymphoma with higher significance (p< 0.05) are amide I of protein, amide II of protein, C-H
bends of CH3/CH2 groups in α- and β- anomers, asymmetric phosphate I, and carbohydrates with
predominant contributions nucleic acids (DNA/RNA via PO2- stretches). Discriminatory regions
of melanoma are amide I and carbohydrates with predominant contributions of nucleic acids[12].

50

Table 3.6 Discriminatory infrared spectral bands of lymphoma and melanoma serum
with biomolecular assignments[12].
Wavenumber region
(cm -1)
i 1700-1600
ii

1480-1580

iii

1325-1380

iv
v

1190-1240
1000-1140

Assignments (taken from references[33, 157-161])
Amide I of proteins: (α-helical, β-pleated sheet, β-turns, random
coils and side-chain structures), ν(C=O), ν(C-N), CNN.
Amide II of proteins: (α-helical, β-pleated sheet, unordered
conformation structures), δ(N-H), ν(C-N).
C-H deformation: due to CH3/CH2 bending (groups in α and β
anomers) of lipids and proteins.
Asymmetric phosphate I: νas(PO2-) of lipid phosphates.
Carbohydrates and nucleic acids: C-O, C-C stretch, C-H bends,
deoxyribose/ribose DNA, RNA, νs(PO2-).

Protein Secondary Structure Analysis by Deconvolution of Amide I Band: In order to
demonstrate alterations in structural components due to malignancy, integral values of α–helical
and β–sheet structures and their ratios were statistically analyzed. Figure 3.10 (a) and 3.10 (b)
show the cluster plots of the integrals of α–helical and β–sheet structures respectively for the
control, B16 and EL4 mice. These figures clearly demonstrate a separation between the
corresponding integral values for the control and tumorous groups for β–sheet and α–helix.
Furthermore, the ratio of integral values α–helix to β–sheet (figure 3.10 (c)) is always less than the
control values for both mouse models with greater than 99% significance.
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Figure 3.10 Plots of the protein secondary structures (α-helix, β-sheet) and their ratio[12].
(a) Quantified integral (area covered) values of α-helix components are less for tumorous cases
compared to control. (b) Integral values of β-sheet components are higher for tumorous cases
compared to control (c) Bar graph representation of average integral ratios between α-helix and
β-sheet for the control, B16 and EL4. Significant alteration in integral ratio (α-helix/β-sheet) is
found between control and tumorigenic case.

Amide I and II Absorbance Values: Amide I and Amide II are the two major bands of
the infrared spectrum for protein interrogation in biological materials[157, 158]. The intensity and
position of these bands, determined by backbone conformation of the hydrogen bonding pattern
change with malignancies[62, 163]. Amide I band position shifts towards the lower wavenumber
due to malignancy. The average position of amide I representing control is at 1641 cm-1, B16 is
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1640 cm-1 and that of EL4 is 1638 cm-1, but the position of amide II stays the same at 1538 cm-1
for all three types. Altered position of amide I is statistically significant for EL4 (*p = 0.001) while
that of B16 is not significant (*p =0.2). Similarly, the altered ratio between amide I and amide II
absorbance values are significant (*p = 0.01) for EL4 lymphoma, but not (*p = 0.3) for B16
melanoma in comparison to the control groups.
Nucleic Acids and Carbohydrate Analysis: In the region 1140-1000 cm-1, there are
plenty of overlapping vibrational modes of biological macromolecules[23] with the major
contribution of nucleic acids and carbohydrates[24]. Bands approximately at 1121 cm-1 arise from
RNA absorbance, whereas the band at 1020 cm-1 arises from DNA absorbance[145]. The spectral
band near 1080 cm-1 is due to νs(PO2-), and the band approximately at 1056 cm-1 corresponding to
the νs(PO2-) absorbance of phosphodiesters of nucleic acids and the O-H stretching coupled with
C-O bending of C-OH groups of carbohydrates[164]. Similarly, absorbance near 1033 cm-1 and
1076 cm-1 are due to the presence of glucose (C-O stretching carbohydrate, β-anomer) and
mannose (C-O stretching carbohydrate α-anomer). Alteration in the concentration of two
sequences of basic genetic materials- (a) RNA (which play an active role in protein synthesis) and
(b) DNA (which is primarily involved in the storage, copying and transferring genetic
information), has been already reported from the tissue analysis of NHL[145] and subcutaneous
melanoma[165]. Due to the fluctuation in these biomolecules, there is a dissimilarity between
malignant groups from their control types. In order to verify these dissimilarities, we have used
Hierarchical Cluster Analysis (HCA) along with spectral deconvolution within this spectral range.
Dendrogram of hierarchical cluster analysis: HCA is commonly employed to identify
the similarities between the FTIR spectra by using the distances between spectra and aggregation
algorithms[63]. The dendrogram of HCA is performed with ATR-FTIR spectra of control, B16,
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and EL4 mice are shown in figure 3.11. Dendrogram tree diagram performed using spectral region
of nucleic acids and carbohydrates, 1140-1000 cm-1, using Ward’s algorithm and squared
Euclidian distance measurements, allow us to visualize of overall grouping structure, including the
sub-groups. The distinct cluster for the control spectra which are grouped together, describing a
high degree of similarity within the groups. Similarly, there is a distinct clustering in the cancer
spectra showing the higher degree of heterogeneity between spectra of cancerous groups.

Figure 3.11 Dendrogram of hierarchical cluster analysis[12]. The dendrogram tree
diagram performed within spectral range 1140-1000 cm-1, by using Ward’s algorithm and squared
Euclidian distance measurements. The spectra are correctly classified. Control spectra appear
grouped together, which describes a high degree of similarity within the groups. Similarly, there
is a distinct clustering in the cancer spectra in two subgroups showing the higher degree of
heterogeneity between cancerous spectra.
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Figure 3.12 The integral sum of Gaussian energy profiles used to fit experimental curves
within 1000-1140 cm-1. (a) The sum of integral values of control groups cluster within the
approximate range 12-14, B16 covers the range 15-17 and EL4 covers 15-18. (b) Bar graph
representation of the average value of the integral sum which shows significant differences
between control and tumorigenic case[12].

Furthermore, to quantify tumor-associated alteration within this complex spectral region
of 1140-1000 cm-1, deconvolution of experimental spectra into Gaussian function band profiles is
further employed. Six Gaussian function energy band profiles (figure 5(b)) are used to fit the
spectra by approximating number and position using the minima of second derivatives (figure
5(a)). The sum of the integral areas covered by six bands (integral values) is then statistically
analyzed to evaluate the tumor-associated alteration in the serum. A calibration curve is obtained,
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as shown in figure 3.12(a) between control and tumorous groups. A clear separation between
control (12-14) and cases of tumorigenicity B16 (15-17) and EL4 (15-18) is found while adding
integral values. The bar graph representation of these values with significance greater than 99% is
shown in figure 3.12(b).

Table 3.7 Quantified values of discriminatory features. Clear separation can be seen
between control and cancerous cases (both B16 and EL4) while comparing integral values of αhelix, β-sheet structure components, and their ratios. Similarly, the altered position of amide I
peak, amide I/amide II ratio and absorbance values at 1212 and 1335 cm-1 show significant
difference only between EL4 and control.
Feature

Control
B16
EL4

3.3

Spectral deconvolution
Amide I
Mixed
-1
1600-1700 cm
region
1000-1140
Integral values
Ratio
Integral
sum
α-helix β-sheet (α/β)
40.616.32.212.2-13.9
44.9
19.3
2.7
38.919-20.2 1.914.8-16.8
40.2
2.1
38.119.11.714.8-17.1
39.9
21.1
2.1

Amide I and II
Position
Ratio:
amide I
abs
Amide
I/II
16401645
16381644
16361642

1.10-1.13
1.10-1.15
1.12-1.15

Absorbance
νas
C-H
(PO2 )
def.
~1212 ~1335
cm-1
cm-1
0.420.44
0.420.45
0.430.46

0.540.59
0.540.59
0.580.59

Spectral Signatures of BC in Serum of Human Patients

Using absorbance spectral data of serum samples (using n = 10 each BC and controls), we
investigate the applicability of FTIR spectroscopy to discriminate between the control and cancer
sera. ATR sample mode of FTIR spectroscopy is used, and the discrimination between the control
and test groups were done using various data analysis techniques. The investigation involves
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multivariate analysis, p-value calculation, quantification by spectral deconvolution and is followed
by statistical analysis.

Figure 3.13 PCA analysis of second derivatives curves of FTIR absorbance spectra[13].
(A) PCA scores plots (PC1 x PC2) with 95% confidence ellipse. The data related to control groups
(• • black dots enclosed by a black shaded ellipse) and BC (▪ ▪ red dots surrounded by a red-shaded
ellipse) are clustered together with different magnitudes and directions. (B) Scree plot of
eigenvalues showing the percentage variance of components one and two is significant compared
to others.

Principal Component Analysis: (PCA), a useful statistical analysis[137], is first
performed to explain the holistic evaluation of protein structural content variations reflected in
amides (amide I and II region, 1480-1600 cm-1). Herein, each of the ten samples is measured twice
(measurement replicates) to obtain 20 spectral data of BC and 20 of control. Using the “PAST
(PAleontological STatistics) 4 - the Past of the Future” software and the vector normalized second
derivative curve of the absorbance spectra within 1480-1600 cm-1, as input data variables, we
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analyzed the variance-covariance matrix with the pairwise exclusion of missing values to get the
component plots. The output of the component plot with 95% ellipses is showing (Figure 3.13 (A))
a clear separation between each studied group. The scatter plot of PC1 (variability 88%) and PC2
(variability 6%) shows the data related to control and BC groups are clustered together with
different magnitudes and directions. Figure 3.13 (B) is the scree plot showing the total variance
presented by PC1 and PC2 are significant. These findings from the PCA analysis of amide bands
have led us to investigate spectral signatures useful in the clinical domain.
Discrimination of Average Absorbance: The average of normalized absorbance spectra
for both control and BC sera that includes the fingerprint region of biological functional groups
(lipids, proteins, nucleic acids, and carbohydrates) is shown in Figure 3.14(A). Solely by looking
at the FTIR spectra, it is difficult to discriminate between the absorbance of the functional
components of the two groups. However, the comparison of the absorbance spectra between the
two groups using student’s t-test (with two-tailed unequal variance) revealed the discriminating
potential at amide regions (1541-1656 cm-1) and the mixed regions of carbohydrates and nucleic
acids (1018-1076 cm-1), as highlighted by the red ellipses in (p <0.05) Figure 3.14 (B). The
prominent, discriminatory regions include C=O/C-N stretching, and N-H bends in amides,
RNA/DNA nucleotides, and C-O vibrations of carbohydrates[153], as reported in previous
studies[89]. Previous studies using principal component analysis-linear discriminant analysis
(PCA-LDA) of FTIR spectra have shown that healthy and cancerous serum samples had different
characteristics[89].
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Figure 3.14 Identification of discriminatory bands. (A) Ensemble averages of normalized
serum spectra derived from control, n = 10 and BC, n = 10. This wider range of spectra is
presented to show the quality of the spectra, which overcomes the noise and atmospheric
contamination while measuring them at resolution 4 cm-1. (B) Corresponding student t-test pvalues for the control and BC. (C) The second derivative absorbance spectra confined to the
amide-I region, covering 1600-1700 cm-1. (D) Difference between the absorbance spectra of
control and BC, indicating up- and down-regulation of proteins, carbohydrates, and nucleic acids
in the serum of BC patients. Figure is taken from our own publication[13].

Molecular assignments of major spectral bands showing discrimination between control and
BC, with higher significance (i.e., p-values < 0.05), are also presented in Table 3.8. These are the
bands originating from amides of protein, carbohydrates, and nucleic acids. The amide vibrations
are mainly arising from C=O stretching vibration, with minor contributions from out-of-phase CH stretching vibrations, C-C-N deformation, and N-H in-plane bend[25]. Similarly, the mixed
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regions of carbohydrates and nucleic acids result from C-O/C-C stretching, C-H bends, and
νs(PO2−)[154]. The second derivative spectra of these absorbance curves revealed that the
absorbance at the minima positions at wavenumber 1629 cm-1 and 1652 cm-1 differ between
healthy individuals and BC patients (Figure 3.14 (C)). Elevation of absorbance values at the energy
band 1018-1076 cm-1 (Figure 3.14(D)) suggests differences in glycomic profiling[166] and
circulating DNA[167] in the blood components. Circulating DNA and glycomic profiling has
proven to be critical molecular markers[166, 167] in several tumor entities.

Table 3.8 Discriminatory IR bands for BC serum samples from controls, and primary
biomolecular assignments, giving rise to the main contributions for the absorbance. Amide
regions and the complex region of carbohydrates and nucleic acids show the discriminating
potential[13].
Wavenumber (cm-1)

Biomolecular Assignments

1700-1600

Amide I: Sensitive to protein secondary structures of proteins, which
arises mainly due to C=O stretching vibrations and by the C-N groups.

1580 -1480

Amide II: Sensitive for protein conformation, originates mainly from
the in-plane N-H bending mode along with C-N and C-C stretching
vibrations.
Carbohydrates: Sensitive to C-O, C-C stretch, C-H bends and
Nucleic acids: Sensitive to deoxyribose/ribose DNA, RNA, νs(PO2-).

1140-1000

Discrimination of Protein Secondary Structures: Figure 3.15 (A), the average of the second
derivative spectra at the amide I absorbance region is shown. The minima of the second derivatives
of spectra allow us to approximate the positions and numbers of Gaussian function energy profiles
required to fit the experimental curve. The amide I band of each spectrum was deconvoluted so
that the baseline-corrected spectra were fitted with 6 GFEB profiles by estimating the number and
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position of the minima of second derivatives, which was simulated (▪▪▪) to fit the experimental
curve (—) as shown in Figure 3.15(B).

Figure 3.15 Protein secondary structure analysis[13]. (A) Representative second
derivatives of absorbance spectra at the amide-I absorbance region. (B) Deconvolution of the
amide-I region: the baseline-corrected spectra fitted with 6 GBEF by approximating number and
position of minima of second derivatives, which simulated fits (▪▪▪) to the experimental curve ( ̶ ).
(C) Integral area of GBEF representing α helix and β sheet. (D) The ratio of α helix and β sheet
energy bands, which proves an elevation of β sheet and drop off α helix structures due to
malignancies. (E) The ratio of IR absorbance at amide II (I1556) to its value at amide III (I1295). (F)
ROC curves for the ratio of the integral area of energy bands representing α-helix and β-sheet
protein secondary structures and the respective absorbance at amide II and amide III. The
maximum values of sensitivity and specificity are 90% and 90% for signature α/β, while these
values are 100% and 80% for signature I1556/ I1295, respectively.

In order to assess any alterations in structural components associated with malignancy, the
integral values of α–helix and β–sheet structures and their ratios were analyzed. Due to the fact

61
that the intensity of the GFEB has a linear relationship with the concentration according to the
Beer-Lambert law[168], the width of GFEB and full width half maximum (FWHM), is inversely
related to the vibrational mode lifetime, which is a function of the ‘rigidity’ of the vibrating
bond[103]. The interaction of the molecule with its immediate environment also affects the width
of GFEB[169]. If a molecule transfers energy to its surroundings, the spectral peak has a broader
line width and reduced intensity, even though the concentration of the molecule remains
unchanged. In such cases, the integral area under the curve is a better indicator of the concentration
than the intensity alone. Interestingly, we found that even though the levels of most structures did
not differ between the samples from BC patients and healthy individuals, BC samples had an
increase in β–sheet structures, while the levels of α-helix structures were decreased (Figure 3.15
(C) and 3.15 (D)). Furthermore, the amide II region is used to report on protein unfolding based
on the extent of hydrogen exchanged. Because of the lack of water interference amide III region
is also considered as a promising region to analyze protein structures. Herein, we have also used a
ratio of IR absorbance at the amide II (I1556) to its value at the amide III (I1295) for analysis of BC
associated protein alteration. The dot plots of these amides ratios are shown in figure 3.15(E).
ROC Curves and AUC Values: Sensitivity and specificity of a diagnostic test are often
used to describe the diagnostic accuracy/performance of the analysis in biomedical research. The
discriminating potential of a diagnostic regimen can be quantified by the AUC values of ROC
curves [142]. The ROC curve is plotted to find the AUC, as in Figure 3.15(F). The optimal cutoff
value calculated for each spectral signature is used to select the positivity/negativity of the disease
and to estimate the sensitivity and specificity. Strong discrimination between diseased and control
serum can be seen with 90% sensitivity and 90% specificity for signature α/β, and these values are
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100% and 80% for I1556/ I1295, respectively. The results indicated that the spectral signatures in the
specified bands have high diagnostic accuracy.

Figure 3.16 Understanding protein secondary structures and physics of IR interaction. (A)
Parallel β-pleated sheet structure of proteins. N-H groups in the backbone of one strand form
hydrogen bonds with the C=O groups in the backbone of the adjacent strand to form a β-sheet.
(B) Right-handed α-helix structures of proteins. The backbone N-H group donates a hydrogen
bond to the backbone C=O group, contributing to the helical structure of the α-helix[13].

As shown in Figure 3.16, the backbone N-H group donates a hydrogen bond to the
backbone C=O group to form the helical structure of the α-helix (Figure 3.16 B). In contrast, the
backbone N-H groups of one strand can form hydrogen bonds with the backbone C=O groups of
the adjacent strands, resulting in β-sheet structures (Figure 3.16 A). Therefore, the cancerassociated alterations in the integral ratio of α-helix and β-sheet protein secondary structures
suggest that protein conformational alterations accompanying changes in their biological function
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might be a key event during the development of cancer. Several studies have shown that proteins
in serum change during BC[88-90, 170]. The alterations in the conformational compositions are
presumably due to alteration in the concentration of cancer embryonic antigen (CEA) proteins[84].
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4

DISCUSSION

In this section, the results, possible clinical applications, optimization of the technique for
clinical applications are discussed. This includes several projects, that have been working on
while preparing this dissertation.
4.1

Discussion Based on DSS Study

This study demonstrates the application of the IR spectroscopic technique for monitoring
colitis progression on days 0, 3, and 7 of chemical administration on DSS mouse models of colitis.
It also reveals as a preliminary step in anticipating the validity of the test for humans and the
development of a portable prototype which can facilitate an ASSURED, IBD screening.
Monitoring alteration in the unique spectral markers [such as the concentration of carbohydrates
(glucose and mannose) and the alpha-helix to beta-sheet ratio of the protein secondary structure]
reflected in the IR spectra of serum, for colitis during disease progression and suppression will
allow us to understand the feasibility of the presented diagnostic regimens in the clinical domain.
Also, the DSS mouse started to behave differently at day 3 of the chemical feeding, so the present
study using samples on days 0, 3, and 7 of chemical administration, is the foundation for further
research with an increased number of sample size. Further work is in progress to investigate dosedependent aggravation, and disease progression of intermediate stages at day five and its
suppression after twelve days, after stopping the chemical feeding. Herein, the DSS mouse model
eliminates few challenges of the human diseases studies and allows us to conduct disease research
on the controlled environment, but there are several other challenging aspects to translate these
findings into humanistic studies. The change in spectral signatures along with disease progression
and suppression needs to be confirmed with the use of samples of human patients. Thus, in our
future work, spectral signatures will be further confirmed by using serum samples from UC
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patients. Once the unique spectral signatures are identified and confirmed, an ASSURED portable
prototype can be developed in which measurements and data analysis techniques can be automated
in the software, so that a technician will be able to perform the test from depositing the specimen
onto the sample holder to the positive or negative results with a screen touch. This rapid, simple,
cost-effective, and the minimally invasive technique would allow the assessment of disease status
and personalized drug management in the future health care of IBD patients.
4.2

Discussion Based on IL10-/- Study

The application of ATR-FTIR spectroscopy to identify the treatment effect of anti-TNFα
in IL-10-/- genotype IBD mouse model is demonstrated. By measuring spectra of serum samples
of untreated, anti- TNFα treated and normal mice, we have compared the statistical significance
difference between the groups and identify the discriminatory features. Identifying IR spectral
signatures I1033, I1076, I1121/I1020, I1629/I1737, α-helix/β-sheet, and integral sum verify antibody
therapy markedly ameliorated the disease as judged by earlier studies[58]. These data justify more
initial findings and support the feasibility of this regimen for drug management during its
treatment. The study of ATR-FTIR spectroscopy of serum samples thus needs to extend with a
statistically significant number of experimental models and human participants.
Importantly, the standardization of technique for the acquisition of spectral signatures
applicable in the clinical domain is explored. The improved standardization of spectral signature
acquisition is needed to assure the potential clinical application of the technique for IBD screening.
The standardization includes reducing the unwanted experimental and data analysis specific
variances. Herein, using a trial-and-error based approach and the clinically relevant data sets on
ATR-FTIR spectroscopy of serum samples, most optimized parameters were used for data taking
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and their analysis. Diagnostic performance parameters, such as sensitivity, specificity, and AUC
under ROC curves prove the feasibility of the studied technique.
All in all, the present study provides evidence that ATR-FTIR spectroscopy of serum
samples accompanied by data analysis techniques could be a tool to evaluate anti-TNFα therapy
in IBD. The study also provides a detailed insight into technical and instrumentation for its clinical
applications. Understanding the drug signature efficacy by using IR spectroscopy of serum
samples further strengthens the idea of the potential applicability of the technique. It is because;
the access to this screening technique would increase the likelihood of compliance with screening
recommendations for those who are otherwise reluctant to undergo the existing endoscopic tests.
4.3

Discussion Based on Colitis Human Patients Study

Early diagnosis and treatment of IBD is crucial because of its negative effects on one’s
overall personal well-being. Nonetheless, as for earlier diagnosis of IBD, the gold standard
colonoscopy diagnostic tests are not easily available and/or are not attractive for all eligible
populations. These are expensive, invasive, risky, and uncomfortable for patients[171]. Limited
studies have reported alternative approaches[43], which could make way for potential advances in
the medical screening of IBD[44]. However, these studies are not yet able to provide a low cost,
quick, and easy early screening test as an alternative to colonoscopies.
The present, minimally invasive technique identifies spectral signatures as biomarkers
associated with the development of disease and could become applicable for UC screening. This
present technique will not replace traditional colonoscopy techniques but will provide an earlier
indication of disease or an additional level of information about UC patients. Importantly, it can
be regularly performed easily at a lower cost at the physician office during annual checkups to
monitor the health of the patient with the possibility of an early indication of UC. Molecular

67
mapping in the form of IR signatures has the potential to become a routine screening regimen for
the continuous assessment of patients. Further evaluation and resolution of UC can be performed
afterward using established colonoscopy tests.
We identified I1033, I1076, I1121/I1020, I1629/I1737, and integral α/β structures as spectral
signatures for UC, and the corresponding differences between them were statistically analyzed.
Note that experimental mouse model studies also showed that these peaks are unique to UC when
compared with metabolic syndrome and arthritis. The ROC curve, sensitivity, specificity, and pvalue calculations further confirm the validation of our performance testing. All these spectral
signatures’ AUC values range from 0.76 to 0.94. These values serve as important pieces of
evidence to demonstrate the validity of the classifier. The sensitivity and specificity pair[141] and
the p-values of the two-sample t-test also verify that the identified signatures are valid for
diagnostic purposes. Using this quantified information of identified spectral signatures, the
required number of controls and UC cases applicable in medical diagnostic trials[172] can also be
calculated. The sample size estimation for high diagnostic accuracy is discussed in Appendix A.3
in detail.
Overall, these results of preliminary research using human samples resemble our earlier
findings using experimental mouse models of disease and establish this technique as a proof of
concept for further investigation using a larger sample size followed by clinical studies. Following
the same protocol for the sample care, spectral measurements and data analysis, calibration curve
applicable for initial diagnosis, differentiate IBD types, the monitoring of therapeutic response, the
prediction of relapse and the ruling out of any flare-ups can be accomplished. Our study further
paves the way for the development of new diagnostic regimens in the physician’s office for IBD
screening as a preventive step. This simple, risk-free, and cost-effective technique with minimal
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sample preparation and lack of discomfort will be attractive to most of the patient population in
the routine screening for UC and other IBDs. This technique can be carried out by primary care
physicians, as a simple & cost-effective preliminary indicator for UC so that the GI can perform
the colonoscopies for the final verification.
This novel proposed technique not only has the potential as an alternative for early
diagnosis of IBDs but also for identifying the progression status of IBDs, specifically UC and CD.
The future work includes the exploration of spectral signatures for CD differentiation between UC
and CD. It is because, patients undergoing an initial evaluation for IBD will often undergo a series
of diagnostic tests, and a large amount of clinical information obtained may make a physician
uncertain as to whether to label the patient as having CD or UC[37]. In many cases, similar drugs
are used to treat UC and CD, but treatment is not equally efficient and responds differently. It is
known that UC mostly presents with rectal inflammation and continuous lesions, while CD
presents with discontinuous inflammatory lesions and frequently involves the ileocecal area.
Studies further show, the location of inflammation (in UC colon is the only site that is affected and
in the CD it affects anywhere along the digestive tract), the efficacy of drug treatment, aggravation
to the other body parts[173] are also different. One can undergo a single surgery to treat UC,
whereas CD may need multiple surgeries. It was reported that concentrations of some chemicals
were different in UC and CD patients[174, 175], thus differentiating IR spectral markers are
expected.
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4.4

Potential Prototype for the Portable Device Development

2nd derivative
calculation
Baseline
correction

Normalizing
spectra

Curve fitting RMS
minimizing

Isolate data for
given range
Read spectral
data from FTIR

Generate
Gaussian
oscillators

Numerical
integration
Main
program

Specificity/sensit
ivity calculation

Figure 4.1 Structure of the software program showing 9 subroutines to perform each
specific task[11]. Each of these specific programming tasks was individually carried out in our
preliminary work in order to get the conclusion. In the portable device development, all those will
be automated into one program which will be done at a single touch command.

Our study is also directed toward designing and developing a prototype of a
portable tool for facilitating such measurements. As the first stage of the portable device
development, we have studied the possible use of a commercially available portable FTIR
(Brucker ALPHA & Perkin Elmer 2) with ATR setup. The communication with the commercial
software from the FTIR manufacturer will be critical to develop a user-friendly prototype, so
accompanying software can be developed to completely automate the process.
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Start
Scan ATR Spectra
Minimum-maximum normalization within spectral range
1000-1800 cm-1 .
Select and cut amide I region 1600-1700 cm-1 for
protein secondary structure analysis.

spectral range is then baseline corrected
2nd derivative of the experimental spectra are now
performed simultaneously to approximate the
number/position of Gaussian function bands required to
fit it.
Experimental curve is now best fit by using 5 Gaussian
oscillators with the minimization of RMS error
(Lavenberg Maquardt Method).
Calculate area integral of oscillators representatives of
side-chain, β-sheet, random coil, α-helix, and anti //-β
sheet protein secondary structures.

calculate integral ratio R (α Helix / β
Sheet) & statistical analysis
Is
R < 3.9

yes

Positive for
Colitis

No
Is
R > 4.4

yes

Negative for
Colitis

Figure 4.2 Flow chart for the programming to study protein secondary structures[11].
Only the α-helix and β-sheet ratio analysis is shown in the flow chart. Similarly, other biomarker
analysis will also be in the program as needed to achieve the needed confidence limit.
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Figure 4.3 Schematic of measurements and data analysis tool permanently integrated into
the anticipated modified spectroscope. "Sample Scan" tab allows users to enter the patient ID,
select the disease followed by pressing "Start Scan" to initiate the program[11].

Fully automating the spectral measurements and analysis presented above is the second
step to check the feasibility of the proposed portable device. Minimization of the instrumentation
by integrating it with a simple touchscreen (e.g. Windows tablet) will make it a user-friendly
desktop unit. Spectral measurements and data analysis procedures will be automated into a single
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step so that a technician can deposit the sample onto the sample holder and start the measurement
with a simple click to get the result and if needed the biochemical information.
The software program will include 9 subroutines as shown in Figure 4.1 and each will do
a specific task in the data extraction or analyzing stage. Reading a spectral data file from the FTIR,
extract data for a suitable biomarker range depending on the user-selected disease, normalizing
and baseline correction of spectral data subroutines will have simple loops, condition check, and
basics mathematical calculations. The second derivative will be calculated by using divided
difference formulas for discrete data. After finding the number of minimums and their positions,
the program will assign parameters for Gaussian oscillators. The curve fitting subroutine will
iteratively vary the Gaussian curve parameters to minimize the RMS error between the
experimental absorption curve and the corresponding summation of the Gaussian curves. The
Levenberg Marquardt algorithm will be used in this subroutine. The standard numerical integration
technique will be used to find the area under each Gaussian oscillator.
As an example, the flow chart for protein secondary structure analysis is shown in figure
4.2. Other biomarkers already identified and new ones to be identified in the process can also be
included in the program. For debugging and troubleshooting reasons, it is important to be able to
see the output at each stage in addition to the outcome. Also, this allows anyone interested to see
the important data at each stage of the process and to try other changes.
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Figure 4.4 Anticipated portable device with the touch screen showing "Test Report". The
test report can be printed as a hard copy or save the patient record in the hospital database[11].

A schematic of this anticipated portable prototype for the colitis screening by using ATRFTIR spectroscopy is shown in figure 4.3, where the microprocessor (I) controls all the functions
in the instrument, and the software (spectral measurement and data analysis) will run on a
microprocessor (II). The software package developed can be installed on the Windows tablet PC
attached to the portable FTIR. Herein, the "Sample Scan" tab allows users to enter the patient ID,
select the disease, followed by the user pressing "Start Scan" to initiate the program. Pressing
"Start Scan" after depositing a sample on the holder can automatically perform the full data
analysis and will display a laboratory test report as seen in figure 4.4.
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4.5

Discussion Based on Lymphoma and Melanoma Study

The results of the present study shown remarkable differences between the ATR-FTIR
spectra of serum samples representing tumor-bearing mouse models of melanoma (n=8) and NHL
(n=8) from their control (n=15) types. The differentiating signatures between spectra are obtained
by observing (i) p-values comparison, (ii) the spectral position, and ratio analysis of amide peaks
(iii) the fit of the experimental spectra and (iv) the employment of multivariate analysis (HCA).
This difference between control and tumorous cases is evident through the gradual changes in the
intensities of the absorption of mainly proteins, carbohydrates and nucleic acids in the serum. It is
noted that serological tests show the alterations of certain proteins, peptides, and nucleic acids
(DNA, mRNA) for patients with melanoma[176] and lymphoma[177]. Manifestations of these
alterations in biomolecules (serological markers) are most likely due to the tumor-induced
alterations directing towards identifying the spectral signatures.
Herein, this is an experimental demonstration of the rapid and reliable spectroscopic
techniques for the discrimination of B16 melanoma and EL4 lymphoma mice from their control
types. B16 murine tumor model remains indispensable for metastasis and therapeutic studies of
human melanoma skin cancer[178].

Similarly, development of EL4 murine tumor model

considered a huge benefit to the human NHL research cancer. This work is thus expected to lay a
foundation for further research which could lead to the development of diagnostic techniques for
future health care of cancer patients of melanoma and lymphoma using body fluid samples that
can be collected with relatively low risks. It is thus critical to extend the present study to human
patients for the assessment of disease status and personalized drug management. Furthermore, the
study of temporal variation in spectral marker signatures is important for tumor grading, subtyping, and assessing heterogeneity. Further work is in progress (i) to investigate temporal
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variation in serum components along with the progression of the disease by increasing sample size,
(ii) identify the alteration in spectral signatures using human patients, and (ii) to integrate data
analyzing software into the narrow multiband detector. After setting a calibration curve of unique
spectral signatures for NHL or subcutaneous melanoma, bulky instrumentation will be avoided
using specific multiband IR detectors capable of simultaneous detection in the expected narrow
bands. Recent advances in IR technology allow the operation of multiband detectors at room
temperature[179]. Complex statistical analysis of identifying spectral signatures of NHL or
melanoma can also be integrated into the clinical tool as a software application into the computer
program. In terms of clinical application, we can anticipate that the potential technology can be
further developed into a personalized diagnostic tool in which patient-to-patient and within a
patient over time (due to health conditions or other factors) differences in molecular signatures
would allow the assessment of disease status and personalized drug management. To be used as a
patient to the patient screening test, a normal range of spectral signatures unique to the particular
disease should be set by using a statistically significant set of normal serum samples. These average
normal values can be incorporated into the program which can identify the deviations of the test
sample from the average values. Technological advancement of ATR-FTIR spectroscopy of serum
sample to discriminate normal and tumorous conditions will thus support to increase compliance
rate eligible population for tumor screening and to make physician decision for advanced
histological examination using biopsy.
4.6

Discussion Based on BC Study

Protein analysis is considered as a promising technique for understanding the progression
of cancers. Similarly, FTIR spectral analysis is one of the accepted paradigms for the holistic
evaluation of protein structural content at the molecular level in biological samples. Several studies
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have introduced the applicability of FTIR spectroscopy in serum samples accompanied by spectral
analysis techniques for BC discrimination. Reports[89, 97] show the potential application of FTIR
spectroscopy for protein analysis in serum samples from the BC patients. However, cancer
initiation, progression, and response to therapy depend on an array of complex interactions
between constituent biomolecules (proteins, lipids, nucleic acids, and carbohydrates) and not only
at the level of the single (biomarker or target) molecule. Therefore, the feasibility of FTIR
spectroscopy to extract a snapshot of cumulative molecular interactions within serum samples
warrant a thorough investigation, as enabled by interdisciplinary collaboration between
spectroscopists, biologists, and clinicians. It is noted that the evaluation of serological biomarkers
(CA15-3, HSP90A, and PAI-1) do not show consistent differences between BC cases and controls
that can lead up to diagnosis [84]. Our data show alterations in biochemical, and structural,
information of the constituent components of the sample medium. Such, holistic evaluation of
biochemical details with the use of IR spectroscopy can thus have an immense potential for BC
discrimination analysis in the clinical domain.
Deconvolution of spectral range 1140-1000 cm-1: To analyze the snapshot of alterations
reflected in our FTIR spectral data, the complex region[140] of carbohydrates and nucleic acids,
1140-1000 cm-1, was deconvoluted. The BC-associated alterations in the DNA and RNA are
reflected in this region. The circulating DNA and protein markers are generally evaluated to track
the biomolecular events of cancerous patients[180]. Herein, this spectral range is deconvoluted
with six GFEB (Figure 4.5 (A)) by approximating numbers and positions using the minima of
second derivatives. The sum of integral areas covered by six bands (integral values) of control,
samples range from 11.4 to 13.2, while these values in BC samples are from 13 to 14.8. This
quantified information was further statistically analyzed (Figure 4.5(B)), and the result shows a
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clear separation between control and BC. Similarly, figure 4.5 (C) shows the histogram of the
average values of absorbance at wavenumber 1020 cm-1. Absorbance at this energy band is found
to be due to the presence of circulating DNA.

Figure 4.5 (A) Deconvolution of the complex band of carbohydrates and nucleic acids
1000-1140 cm-1. The number and position of six bands used to fit the experimental curve were
determined by using the minima of secondary curves as in amide I case. (B) Bar graph
representation of the average value of the integral sum which shows a significant difference
between control and BC case. (C) Bar graph of average absorbances at wavenumber position
1020 cm-1, which is mainly due to the presence of DNA. It also shows a significant difference
between control and BC cases[13].
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Potential prototype for clinical application: Moreover, a prototype for our presented
diagnostic regimen for clinical use can be developed. Spectral measurements and data analysis
procedures will be automated into a single step so that a technician can deposit the sample onto
the sample holder and start to measure with a simple click to get the result and, if needed, the
biochemical information easily as shown in Figure 4.6. ATR-FTIR spectroscopy (that is reliable
for body-fluids analysis) integrated with two micro-controllers, where micro-controller A controls
all the functions in the FTIR, while the controller B controls software for data analysis. The
software program will include several subroutines as reading spectral data from the FTIR; extract
data for suitable spectral signatures in the measured range; normalizing and baseline correction of
spectral data subroutines will have simple loops, condition checks, and basics mathematical
calculations.

Figure 4.6 Schematic of ATR-FTIR spectrometer integrated with two micro-controllers
(micro-processors) A and B. The controller A extracts the information about the signal-sample
interaction, while controller B stores the spectral analyzing software application in the clinical
domain[13].
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The second derivative will be calculated by using divided difference formulas for discrete
data. After finding various minimums and their positions, the program will assign parameters for
Gaussian energy bands and select settings for bands to minimize RMS error (Levenberg Marquardt
algorithm) between experimental data and fitted curves. The standard numerical integration
technique will be used to find the area under Gaussian bands and the ratio. Additionally, combining
all identified multiple spectral signatures into a single diagnostic index using them as the
discriminating signature marker, a portable device integrated with the user-friendly desktop unit
(can automatically perform the full data analysis and will display laboratory test report) can be
prepared.
All in all, FTIR spectroscopy of serum samples could be a promising technique for an
ASSURED regimen for evaluation of BC associated molecular level of alteration in constituent
protein structures. Our study holds value as available techniques such as mammograms, MRI, and
ultrasonography have their limits and may not be 100% accurate[81, 181-183]. Among them, MRI
achieves a high sensitivity of 70%–100% in the initial screening (prevalence), compared at 40%
or less for mammography in patients with high risk to develop BC[182, 183], but the specificity
of MRI is hampered by its difficulty while distinguishing the overlapping features of benign and
malignant lesions, leading to higher false-positive rates[181]. Ultrasonography also fails to detect
micro-calcifications and has poor specificity. Therefore, the present diagnostic regimen of BC
having the potential to promote timely onward referral of patients for further testing and detection
of recurrent disease, “enabling serial sample and testing with less cost, resource and radiation
exposure” could be beneficial for several patients.
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5

CONCLUSION

The findings presented in this dissertation confirm the potential application of FTIR
spectroscopy of serum samples, accompanied by data analysis techniques, promise for use as a
clinical tool to differentiate IBD and cancer patients from healthy individuals. Importantly, it is
evident through the use of experimental mouse models and human patients. However, the utility
of this technique as a clinical tool requires further investigation and validations. Therefore,
prospective studies evaluating specificity, sensitivity and accuracy of the technique on a large and
carefully case-defined population is warranted. Accurate and objective classification, staging and
grading for cancer management as opposed to the present gold standard, histopathological
diagnosis, to guide treatments and predict patient prognosis is crucial to accelerate point-of-care
decisions and potentially revolutionize cancer diagnostics in personalized medicine by using FTR
spectroscopy.
In the IBD study, the experimental models: IL10-/- and DSS shows diagnostic accuracy
with 80-100% sensitivity and specificity values. In human serum samples, our study shows
sensitivity and specificity values are 100% and 86%, respectively. Similarly, in cancer studies,
mouse models of NHL and subcutaneous melanoma, emphasizes the diagnostic potential of this
approach as a screening technique. Similarly, the BC-associated protein conformational alteration
in the serum samples shows the sensitivity and the specificity of identifying spectral signatures
were both 90%. Various spectral signatures were analyzed as shown in Table 5.1. These include
(a) absorption values at wavenumber 1033 cm-1, (b) absorption values at wavenumber 1076 cm-1;
(c) the ratio of absorbance at wavenumber 1121 cm-1, to its value at 1020 cm-1, (d) the ratio of
absorbance at wavenumber 1629 cm-1, to 1737 cm-1. (e) the ratio of GFEB representing α helix
and β sheet protein secondary structures as obtained from the deconvolution of amide I region, (f)
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the sum of the integral area of GFEBs used to fit the experimental curve within the complex band
of carbohydrates, and nucleic acids 1000-1140 cm-1 (g) absorbance at wavenumber 1212 cm-1, and
the absorbance at wavenumber 1335 cm-1.

Table 5.1 Summary of identifying spectral signatures.
Studied types
I1033

I1076

Yes

Yes

Colitis

Yes

Yes

Discrimination from the controls
I1629/
Integral Amide Amide
I1737
α/β
sum I/II
II/III I1212
….
…..
….
…..
Yes Yes Yes
Yes
…
….
….
Yes Yes Yes

IL10-/- Treated

No

No

No

No

No

No

….

….

….

….

Control

No

No

No

No

No

No

…..

….

….

….

Human Control

No
Yes

No
Yes

No
Yes

No
Yes

….

….

…..

….

….

Human UC

No
Yes

….

….

…..

….

….

Lymphoma

….

….

…..

….

Yes

Yes

Yes

…..

Yes

Yes

Melanoma

….

….

…..

…..

Yes

Yes

No

…..

No

No

Control mice

….

….

….

….

No

No

No

….

No

No

BC

Yes

Yes

…

….

Yes

Yes

….

Yes

….

….

Human Control

No

No

….

…

No

No

….

No

….

….

DSS Colitis

I1121/
I1021

I1335
…..
….

82
REFERENCES
[1]
[2]
[3]
[4]

[5]

[6]

[7]

[8]

[9]
[10]

[11]

[12]

[13]
[14]
[15]
[16]
[17]
[18]

M. S. H. Akash and K. Rehman, "Introduction to Spectrophotometric Techniques," in
Essentials of Pharmaceutical Analysis: Springer, 2020, pp. 19-27.
S. Mukamel, Principles of nonlinear optical spectroscopy. Oxford university press New
York, 1995.
B. C. Smith, Fundamentals of Fourier transform infrared spectroscopy. CRC press,
2011.
J. Titus, H. Ghimire, E. Viennois, D. Merlin, and A. J. J. o. b. Unil Perera, "Protein
secondary structure analysis of dried blood serum using infrared spectroscopy to identify
markers for colitis screening," vol. 11, no. 3, p. e201700057, 2018.
J. Titus, E. Viennois, D. Merlin, and A. J. J. o. b. Unil Perera, "Minimally invasive
screening for colitis using attenuated total internal reflectance fourier transform infrared
spectroscopy," vol. 10, no. 3, pp. 465-472, 2017.
H. Ghimire, X. Hu, G. Qin, and A. U. J. B. O. E. Perera, "Optimizing infrared spectral
discrimination to enhance disease diagnostics: monitoring the signatures of inflammatory
bowel diseases with anti-TNFα therapy," vol. 11, no. 8, pp. 4679-4694, 2020.
A. U. Perera and H. Ghimire, "Quantification of infrared spectral markers for ulcerative
colitis using sera," in Biomedical Vibrational Spectroscopy 2020: Advances in Research
and Industry, 2020, vol. 11236, p. 112360T: International Society for Optics and
Photonics.
A. U. Perera, H. Ghimire, K. Perera, E. Viennois, and D. Merlin, "Colitis screening using
IR spectroscopy of serum samples," in 2017 Eleventh International Conference on
Sensing Technology (ICST), 2017, pp. 1-4: IEEE.
H. Ghimire, K. Perera, and A. J. B. o. t. A. P. S. Perera, "Mid-IR Spectroscopy of Dried
Serum Samples: An Application for Colitis Prescreening," vol. 62, 2017.
J. Titus, H. Ghimire, E. Viennois, D. Merlin, and A. U. Perera, "Infrared spectroscopy as
a screening technique for colitis," in Bio-MEMS and Medical Microdevices III, 2017, vol.
10247, p. 102470C: International Society for Optics and Photonics.
H. Ghimire, P. Jayaweera, A. U. J. I. P. Perera, and Technology, "Longitudinal analysis
of molecular alteration in serum samples of dextran sodium sulfate-induced colitis mice
by using infrared spectroscopy," vol. 97, pp. 33-37, 2019.
H. Ghimire, M. Venkataramani, Z. Bian, Y. Liu, and A. U. Perera, "ATR-FTIR spectral
discrimination between normal and tumorous mouse models of lymphoma and melanoma
from serum samples," Scientific reports, vol. 7, no. 1, pp. 1-9, 2017.
H. Ghimire et al., "Protein Conformational Changes in Breast Cancer Sera Using Infrared
Spectroscopic Analysis," Cancers, vol. 12, no. 7, p. 1708, 2020.
M. H. Niemz, Laser-tissue interactions. Springer, 2007.
B. Stuart, "Infrared spectroscopy," Kirk‐Othmer encyclopedia of chemical technology,
2000.
H. W. Siesler, Y. Ozaki, S. Kawata, and H. M. Heise, Near-infrared spectroscopy:
principles, instruments, applications. John Wiley & Sons, 2008.
P. R. Griffiths and J. A. De Haseth, Fourier transform infrared spectrometry. John Wiley
& Sons, 2007.
M. Blanco and I. Villarroya, "NIR spectroscopy: a rapid-response analytical tool," TrAC
Trends in Analytical Chemistry, vol. 21, no. 4, pp. 240-250, 2002.

83
[19]
[20]
[21]
[22]
[23]

[24]
[25]

[26]

[27]

[28]
[29]

[30]
[31]

[32]

[33]
[34]

[35]

C. Kendall et al., "Vibrational spectroscopy: a clinical tool for cancer diagnostics,"
Analyst, vol. 134, no. 6, pp. 1029-1045, 2009.
J. Dubois and R. A. Shaw, "Peer Reviewed: IR Spectroscopy in Clinical and Diagnostic
Applications," ed: ACS Publications, 2004.
C.-M. J. F. s. i. Orphanou, "The detection and discrimination of human body fluids using
ATR FT-IR spectroscopy," vol. 252, pp. e10-e16, 2015.
F. Parker, Applications of infrared spectroscopy in biochemistry, biology, and medicine.
Springer Science & Business Media, 2012.
Z. Movasaghi, S. Rehman, and D. I. ur Rehman, "Fourier transform infrared (FTIR)
spectroscopy of biological tissues," Applied Spectroscopy Reviews, vol. 43, no. 2, pp.
134-179, 2008.
M. J. Baker et al., "Using Fourier transform IR spectroscopy to analyze biological
materials," Nature protocols, vol. 9, no. 8, p. 1771, 2014.
H. Yang, S. Yang, J. Kong, A. Dong, and S. Yu, "Obtaining information about protein
secondary structures in aqueous solution using Fourier transform IR spectroscopy,"
Nature protocols, vol. 10, no. 3, pp. 382-396, 2015.
J. Trevisan, P. P. Angelov, P. L. Carmichael, A. D. Scott, and F. L. Martin, "Extracting
biological information with computational analysis of Fourier-transform infrared (FTIR)
biospectroscopy datasets: current practices to future perspectives," Analyst, vol. 137, no.
14, pp. 3202-3215, 2012.
J. G. Kelly et al., "Robust classification of low-grade cervical cytology following
analysis with ATR-FTIR spectroscopy and subsequent application of self-learning
classifier eClass," Analytical and bioanalytical chemistry, vol. 398, no. 5, pp. 2191-2201,
2010.
S. G. Kazarian and K. A. Chan, "ATR-FTIR spectroscopic imaging: recent advances and
applications to biological systems," Analyst, vol. 138, no. 7, pp. 1940-1951, 2013.
J. Titus, C. Filfili, J. K. Hilliard, J. A. Ward, and A. Unil Perera, "Early detection of cell
activation events by means of attenuated total reflection Fourier transform infrared
spectroscopy," Applied Physics Letters, vol. 104, no. 24, p. 243705, 2014.
A. W. Snyder and J. D. Love, "Goos-Hänchen shift," Applied optics, vol. 15, no. 1, pp.
236-238, 1976.
G. Clemens, J. R. Hands, K. M. Dorling, and M. J. Baker, "Vibrational spectroscopic
methods for cytology and cellular research," Analyst, vol. 139, no. 18, pp. 4411-4444,
2014.
K. A. Chan and S. G. Kazarian, "Attenuated total reflection Fourier-transform infrared
(ATR-FTIR) imaging of tissues and live cells," Chemical Society Reviews, vol. 45, no. 7,
pp. 1850-1864, 2016.
M. J. Baker et al., "Developing and understanding biofluid vibrational spectroscopy: a
critical review," Chemical Society Reviews, vol. 45, no. 7, pp. 1803-1818, 2016.
D. N. Frank, A. L. S. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace,
"Molecular-phylogenetic characterization of microbial community imbalances in human
inflammatory bowel diseases," Proceedings of the National Academy of Sciences, vol.
104, no. 34, pp. 13780-13785, 2007.
S. H. Itzkowitz and X. Yio, "Inflammation and cancer IV. Colorectal cancer in
inflammatory bowel disease: the role of inflammation," American journal of physiologygastrointestinal and liver physiology, vol. 287, no. 1, pp. G7-G17, 2004.

84
[36]

[37]

[38]
[39]
[40]
[41]
[42]
[43]
[44]

[45]

[46]

[47]

[48]
[49]
[50]
[51]

[52]
[53]

C. G. Loftus et al., "Update on the incidence and prevalence of Crohn's disease and
ulcerative colitis in Olmsted County, Minnesota, 1940–2000," Inflammatory bowel
diseases, vol. 13, no. 3, pp. 254-261, 2007.
A. Bousvaros et al., "Differentiating ulcerative colitis from Crohn disease in children and
young adults: report of a working group of the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of
America," Journal of pediatric gastroenterology and nutrition, vol. 44, no. 5, pp. 653674, 2007.
M. Z. Cader and A. Kaser, "Recent advances in inflammatory bowel disease: mucosal
immune cells in intestinal inflammation," Gut, vol. 62, no. 11, pp. 1653-1664, 2013.
R. Yantiss and R. Odze, "Diagnostic difficulties in inflammatory bowel disease
pathology," Histopathology, vol. 48, no. 2, pp. 116-132, 2006.
S. Vermeire, G. Van Assche, and P. Rutgeerts, "Laboratory markers in IBD: useful,
magic, or unnecessary toys?," Gut, vol. 55, no. 3, pp. 426-431, 2006.
J. A. Wilson, "Colon cancer screening in the elderly: when do we stop?," Transactions of
the American Clinical and Climatological Association, vol. 121, p. 94, 2010.
R. Xavier and D. Podolsky, "Unravelling the pathogenesis of inflammatory bowel
disease," Nature, vol. 448, no. 7152, p. 427, 2007.
A. Tesija Kuna, "Serological markers of inflammatory bowel disease," Biochemia
medica: Biochemia medica, vol. 23, no. 1, pp. 28-42, 2013.
R. Burakoff et al., "Blood-based biomarkers used to predict disease activity in Crohn's
disease and ulcerative colitis," Inflammatory bowel diseases, vol. 21, no. 5, pp. 11321140, 2015.
B. Mesko et al., "Peripheral blood gene expression patterns discriminate among chronic
inflammatory diseases and healthy controls and identify novel targets," BMC medical
genomics, vol. 3, no. 1, p. 15, 2010.
J. Ollesch, M. Heinze, H. M. Heise, T. Behrens, T. Brüning, and K. Gerwert, "It's in your
blood: spectral biomarker candidates for urinary bladder cancer from automated FTIR
spectroscopy," Journal of biophotonics, vol. 7, no. 3‐4, pp. 210-221, 2014.
S. Kazarian and K. Chan, "Applications of ATR-FTIR spectroscopic imaging to
biomedical samples," Biochimica et Biophysica Acta (BBA)-Biomembranes, vol. 1758,
no. 7, pp. 858-867, 2006.
C.-M. Orphanou, "The detection and discrimination of human body fluids using ATR FTIR spectroscopy," Forensic science international, vol. 252, pp. e10-e16, 2015.
E. A. Martin, Concise medical dictionary. Oxford Quick Reference, 2015.
L. L. Banez et al., "Diagnostic potential of serum proteomic patterns in prostate cancer,"
The Journal of urology, vol. 170, no. 2, pp. 442-446, 2003.
A. Lembo, B. Neri, J. Tolley, D. Barken, S. Carroll, and H. Pan, "Use of serum
biomarkers in a diagnostic test for irritable bowel syndrome," Alimentary pharmacology
& therapeutics, vol. 29, no. 8, pp. 834-842, 2009.
A. Tagore et al., "Interleukin‐10 (IL‐10) genotypes in inflammatory bowel disease,"
Tissue antigens, vol. 54, no. 4, pp. 386-390, 1999.
W. E. Ip, N. Hoshi, D. S. Shouval, S. Snapper, and R. Medzhitov, "Anti-inflammatory
effect of IL-10 mediated by metabolic reprogramming of macrophages," Science, vol.
356, no. 6337, pp. 513-519, 2017.

85
[54]

[55]
[56]

[57]

[58]
[59]
[60]
[61]

[62]

[63]
[64]
[65]

[66]

[67]

[68]

[69]

E. Viennois, M. T. Baker, B. Xiao, L. Wang, H. Laroui, and D. J. J. o. p. Merlin,
"Longitudinal study of circulating protein biomarkers in inflammatory bowel disease,"
vol. 112, pp. 166-179, 2015.
H. M. Van Dullemen et al., "Treatment of Crohn's disease with anti-tumor necrosis factor
chimeric monoclonal antibody (cA2)," vol. 109, no. 1, pp. 129-135, 1995.
A. Akazawa, I. Sakaida, S. Higaki, Y. Kubo, K. Uchida, and K. J. J. o. g. Okita,
"Increased expression of tumor necrosis factor-α messenger RNA in the intestinal
mucosa of inflammatory bowel disease, particularly in patients with disease in the
inactive phase," vol. 37, no. 5, pp. 345-353, 2002.
K. Aden et al., "Metabolic functions of gut microbes associate with efficacy of tumor
necrosis factor antagonists in patients with inflammatory bowel diseases," vol. 157, no. 5,
pp. 1279-1292. e11, 2019.
L. Peyrin-Biroulet, "Anti-TNF therapy in inflammatory bowel diseases: a huge review,"
Minerva gastroenterologica e dietologica, vol. 56, no. 2, pp. 233-243, 2010.
R. Kühn, J. Löhler, D. Rennick, K. Rajewsky, and W. Müller, "Interleukin-10-deficient
mice develop chronic enterocolitis," Cell, vol. 75, no. 2, pp. 263-274, 1993.
P. J. Koelink et al., "Anti-TNF therapy in IBD exerts its therapeutic effect through
macrophage IL-10 signalling," Gut, pp. gutjnl-2019-318264, 2019.
T. Scheinin, D. M. Butler, F. Salway, B. Scallon, and M. Feldmann, "Validation of the
interleukin‐10 knockout mouse model of colitis: antitumour necrosis factor‐antibodies
suppress the progression of colitis," Clinical & Experimental Immunology, vol. 133, no.
1, pp. 38-43, 2003.
B. Wood, L. Chiriboga, H. Yee, M. Quinn, D. McNaughton, and M. Diem, "Fourier
transform infrared (FTIR) spectral mapping of the cervical transformation zone, and
dysplastic squamous epithelium," Gynecologic oncology, vol. 93, no. 1, pp. 59-68, 2004.
P. D. Lewis et al., "Evaluation of FTIR spectroscopy as a diagnostic tool for lung cancer
using sputum," BMC cancer, vol. 10, no. 1, p. 640, 2010.
J. Backhaus et al., "Diagnosis of breast cancer with infrared spectroscopy from serum
samples," Vibrational Spectroscopy, vol. 52, no. 2, pp. 173-177, 2010.
C. A. Lima, V. P. Goulart, L. Côrrea, T. M. Pereira, and D. M. Zezell, "ATR-FTIR
spectroscopy for the assessment of biochemical changes in skin due to cutaneous
squamous cell carcinoma," International journal of molecular sciences, vol. 16, no. 4, pp.
6621-6630, 2015.
N. Fujioka, Y. Morimoto, T. Arai, and M. Kikuchi, "Discrimination between normal and
malignant human gastric tissues by Fourier transform infrared spectroscopy," Cancer
Detection and Prevention, vol. 28, no. 1, pp. 32-36, 2004.
E. Gazi et al., "Applications of Fourier transform infrared microspectroscopy in studies
of benign prostate and prostate cancer. A pilot study," The Journal of pathology, vol. 201,
no. 1, pp. 99-108, 2003.
B. Rigas, S. Morgello, I. S. Goldman, and P. Wong, "Human colorectal cancers display
abnormal Fourier-transform infrared spectra," Proceedings of the National Academy of
Sciences, vol. 87, no. 20, pp. 8140-8144, 1990.
G. Theophilou, K. M. Lima, P. L. Martin-Hirsch, H. F. Stringfellow, and F. L. Martin,
"ATR-FTIR spectroscopy coupled with chemometric analysis discriminates normal,
borderline and malignant ovarian tissue: classifying subtypes of human cancer," Analyst,
vol. 141, no. 2, pp. 585-594, 2016.

86
[70]

[71]

[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]

[80]
[81]
[82]

[83]
[84]
[85]
[86]

[87]
[88]

[89]

A. J. Sommer, L. G. Tisinger, C. Marcott, and G. M. Story, "Attenuated total internal
reflection infrared mapping microspectroscopy using an imaging microscope," Applied
spectroscopy, vol. 55, no. 3, pp. 252-256, 2001.
M. Lens and M. Dawes, "Global perspectives of contemporary epidemiological trends of
cutaneous malignant melanoma," British Journal of Dermatology, vol. 150, no. 2, pp.
179-185, 2004.
R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016," CA: a cancer journal
for clinicians, vol. 66, no. 1, pp. 7-30, 2016.
C. Garbe and U. Leiter, "Melanoma epidemiology and trends," Clinics in dermatology,
vol. 27, no. 1, pp. 3-9, 2009.
S. G. Fisher and R. I. Fisher, "The epidemiology of non-Hodgkin's lymphoma,"
Oncogene, vol. 23, no. 38, pp. 6524-6534, 2004.
N. Howlader et al., "SEER Cancer Statistics Review, 1975-2013, National Cancer
Institute. Bethesda, MD," ed, 2016.
A. F. Jerant, J. T. Johnson, C. Sheridan, and T. J. Caffrey, "Early detection and treatment
of skin cancer," American family physician, vol. 62, no. 2, pp. 357-386, 2000.
M. Shipp et al., "A predictive model for aggressive non-Hodgkin's lymphoma," New
England Journal of Medicine, vol. 329, no. 14, pp. 987-994, 1993.
B. Stewart and C. P. Wild, "World cancer report 2014," Public Health, 2019.
S. McGuire, "World cancer report 2014. Geneva, Switzerland: World Health
Organization, international agency for research on cancer, WHO Press, 2015," ed: Oxford
University Press, 2016.
A. C. Society, "Breast cancer facts & figures 2017–2018," ed: American Cancer Society
Atlanta, GA, 2017.
B. C. Yankaskas et al., "Performance of first mammography examination in women
younger than 40 years," vol. 102, no. 10, pp. 692-701, 2010.
A. B. Miller, C. Wall, C. J. Baines, P. Sun, T. To, and S. A. J. B. Narod, "Twenty five
year follow-up for breast cancer incidence and mortality of the Canadian National Breast
Screening Study: randomised screening trial," vol. 348, p. g366, 2014.
D. E. Misek and E. H. Kim, "Protein biomarkers for the early detection of breast cancer,"
International journal of proteomics, vol. 2011, 2011.
A. Kazarian et al., "Testing breast cancer serum biomarkers for early detection and
prognosis in pre-diagnosis samples," vol. 116, no. 4, pp. 501-508, 2017.
G. C. Blobe, L. M. Obeid, and Y. A. Hannun, "Regulation of protein kinase C and role in
cancer biology," Cancer and Metastasis Reviews, vol. 13, no. 3-4, pp. 411-431, 1994.
J. Bartkova, J. Lukas, H. Müller, D. Lützhøt, M. Strauss, and J. Bartek, "Cyclin D1
protein expression and function in human breast cancer," International journal of cancer,
vol. 57, no. 3, pp. 353-361, 1994.
J. Jacquemier et al., "Protein expression profiling identifies subclasses of breast cancer
and predicts prognosis," Cancer Research, vol. 65, no. 3, pp. 767-779, 2005.
J. Li, Z. Zhang, J. Rosenzweig, Y. Y. Wang, and D. W. J. C. c. Chan, "Proteomics and
bioinformatics approaches for identification of serum biomarkers to detect breast cancer,"
vol. 48, no. 8, pp. 1296-1304, 2002.
F. Elmi, A. F. Movaghar, M. M. Elmi, H. Alinezhad, N. J. S. A. P. A. M. Nikbakhsh, and
B. Spectroscopy, "Application of FT-IR spectroscopy on breast cancer serum analysis,"
vol. 187, pp. 87-91, 2017.

87
[90]
[91]
[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]
[101]
[102]
[103]
[104]
[105]
[106]

U. Zelig et al., "Early detection of breast cancer using total biochemical analysis of
peripheral blood components: a preliminary study," vol. 15, no. 1, p. 408, 2015.
E. Ostrovsky et al., "Detection of cancer using advanced computerized analysis of
infrared spectra of peripheral blood," vol. 60, no. 2, pp. 343-353, 2012.
T. Gao, J. Feng, and Y. J. A. c. p. Ci, "Human breast carcinomal tissues display
distinctive FTIR spectra: implication for the histological characterization of carcinomas,"
vol. 18, no. 2, pp. 87-93, 1999.
R. Eckel, H. Huo, H.-W. Guan, X. Hu, X. Che, and W.-D. J. V. S. Huang, "Characteristic
infrared spectroscopic patterns in the protein bands of human breast cancer tissue," vol.
27, no. 2, pp. 165-173, 2001.
D. J. Lyman and J. J. A. s. Murray-Wijelath, "Fourier transform infrared attenuated total
reflection analysis of human hair: comparison of hair from breast cancer patients with
hair from healthy subjects," vol. 59, no. 1, pp. 26-32, 2005.
S. M. Han et al., "Synchrotron nanoscopy imaging study of scalp hair in breast cancer
patients and healthy individuals: Difference in medulla loss and cortical membrane
enhancements," vol. 79, no. 1, pp. 23-30, 2016.
D. C. Malins, N. L. Polissar, S. Schaefer, Y. Su, and M. Vinson, "A unified theory of
carcinogenesis based on order–disorder transitions in DNA structure as studied in the
human ovary and breast," Proceedings of the National Academy of Sciences, vol. 95, no.
13, pp. 7637-7642, 1998.
M. Kotkova, V. Sitnikova, T. Nosenko, T. Kotkova, M. Uspenskaya, and R.
Olekhnovich, "Spectroscopic Study of Blood Serum of Patients With Breast Cancer," in
2018 IEEE-EMBS Conference on Biomedical Engineering and Sciences (IECBES), 2018,
pp. 657-660: IEEE.
A. L. Mitchell, K. B. Gajjar, G. Theophilou, F. L. Martin, and P. L. Martin‐Hirsch,
"Vibrational spectroscopy of biofluids for disease screening or diagnosis: translation
from the laboratory to a clinical setting," Journal of biophotonics, vol. 7, no. 3‐4, pp.
153-165, 2014.
M. Aaboe, B. V. Offersen, A. Christensen, and P. A. Andreasen, "Vitronectin in human
breast carcinomas," Biochimica et Biophysica Acta (BBA)-Molecular basis of disease,
vol. 1638, no. 1, pp. 72-82, 2003.
M. Karplus and J. A. McCammon, "Molecular dynamics simulations of biomolecules,"
Nature Structural & Molecular Biology, vol. 9, no. 9, p. 646, 2002.
J. Drenth, Principles of protein X-ray crystallography. Springer Science & Business
Media, 2007.
K. Wüthrich, "NMR with proteins and nucleic acids," Europhysics News, vol. 17, no. 1,
pp. 11-13, 1986.
A. J. B. e. B. A.-B. Barth, "Infrared spectroscopy of proteins," vol. 1767, no. 9, pp. 10731101, 2007.
A. J. J. L. o. B. M. Jabs, "Determination of secondary structure in proteins by fourier
transform infrared spectroscopy (FTIR)," 2005.
J. A. Hering and P. I. Haris, "FTIR spectroscopy for analysis of protein secondary
structure," Biological and biomedical infrared spectroscopy, pp. 129-167, 2009.
W. K. Surewicz, H. H. Mantsch, and D. Chapman, "Determination of protein secondary
structure by Fourier transform infrared spectroscopy: a critical assessment,"
Biochemistry, vol. 32, no. 2, pp. 389-394, 1993.

88
[107] D. C. Lee, P. I. Haris, D. Chapman, and R. C. Mitchell, "Determination of protein
secondary structure using factor analysis of infrared spectra," Biochemistry, vol. 29, no.
39, pp. 9185-9193, 1990.
[108] R. Pribic, I. Vanstokkum, D. Chapman, P. I. Haris, and M. Bloemendal, "Protein
secondary structure from Fourier transform infrared and/or circular dichroism spectra,"
Analytical biochemistry, vol. 214, no. 2, pp. 366-378, 1993.
[109] L. M. Miller, M. W. Bourassa, and R. J. Smith, "FTIR spectroscopic imaging of protein
aggregation in living cells," Biochimica et Biophysica Acta (BBA)-Biomembranes, vol.
1828, no. 10, pp. 2339-2346, 2013.
[110] P. I. Haris and F. Severcan, "FTIR spectroscopic characterization of protein structure in
aqueous and non-aqueous media," Journal of Molecular Catalysis B: Enzymatic, vol. 7,
no. 1-4, pp. 207-221, 1999.
[111] F. Garczarek and K. Gerwert, "Functional waters in intraprotein proton transfer
monitored by FTIR difference spectroscopy," Nature, vol. 439, no. 7072, p. 109, 2006.
[112] J. Grdadolnik and Y. Maréchal, "Hydrogen–Deuterium Exchange in Bovine Serum
Albumin Protein Monitored by Fourier Transform Infrared Spectroscopy, Part I:
Structural Studies," Applied spectroscopy, vol. 59, no. 11, pp. 1347-1356, 2005.
[113] S. J. Prestrelski, N. Tedeschi, T. Arakawa, and J. F. Carpenter, "Dehydration-induced
conformational transitions in proteins and their inhibition by stabilizers," Biophysical
journal, vol. 65, no. 2, pp. 661-671, 1993.
[114] R. Lu, W.-W. Li, A. Katzir, Y. Raichlin, H.-Q. Yu, and B. Mizaikoff, "Probing the
secondary structure of bovine serum albumin during heat-induced denaturation using
mid-infrared fiberoptic sensors," Analyst, vol. 140, no. 3, pp. 765-770, 2015.
[115] H. Fabian, C. Schultz, D. Naumann, O. Landt, U. Hahn, and W. Saenger, "Secondary
structure and temperature-induced unfolding and refolding of ribonuclease T1 in aqueous
solution: A Fourier transform infrared spectroscopic study," Journal of molecular
biology, vol. 232, no. 3, pp. 967-981, 1993.
[116] M. J. Baker, E. Gazi, M. D. Brown, J. H. Shanks, P. Gardner, and N. W. Clarke, "FTIRbased spectroscopic analysis in the identification of clinically aggressive prostate cancer,"
British journal of cancer, vol. 99, no. 11, p. 1859, 2008.
[117] L.-P. i. Choo, D. L. Wetzel, W. C. Halliday, M. Jackson, S. M. LeVine, and H. H.
Mantsch, "In situ characterization of beta-amyloid in Alzheimer's diseased tissue by
synchrotron Fourier transform infrared microspectroscopy," Biophysical Journal, vol. 71,
no. 4, pp. 1672-1679, 1996.
[118] M. Szczerbowska-Boruchowska et al., "Biomolecular investigation of human substantia
nigra in Parkinson’s disease by synchrotron radiation Fourier transform infrared
microspectroscopy," Archives of biochemistry and biophysics, vol. 459, no. 2, pp. 241248, 2007.
[119] A. Kretlow, Q. Wang, M. Beekes, D. Naumann, and L. M. Miller, "Changes in protein
structure and distribution observed at pre-clinical stages of scrapie pathogenesis,"
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1782, no. 10, pp.
559-565, 2008.
[120] P. I. Haris, "Probing protein–protein interaction in biomembranes using Fourier transform
infrared spectroscopy," Biochimica et Biophysica Acta (BBA)-Biomembranes, vol. 1828,
no. 10, pp. 2265-2271, 2013.

89
[121] M. Jackson, P. I. Haris, and D. Chapman, "Fourier transform infrared spectroscopic
studies of calcium-binding proteins," Biochemistry, vol. 30, no. 40, pp. 9681-9686, 1991.
[122] M. Jackson and H. H. Mantsch, "The use and misuse of FTIR spectroscopy in the
determination of protein structure," Critical reviews in biochemistry and molecular
biology, vol. 30, no. 2, pp. 95-120, 1995.
[123] W. K. Surewicz and H. H. Mantsch, "New insight into protein secondary structure from
resolution-enhanced infrared spectra," Biochimica et Biophysica Acta (BBA)-Protein
Structure and Molecular Enzymology, vol. 952, pp. 115-130, 1988.
[124] H. Fabian and D. Naumann, "Methods to study protein folding by stopped-flow FT-IR,"
Methods, vol. 34, no. 1, pp. 28-40, 2004.
[125] S. Zhang and A. Rich, "Direct conversion of an oligopeptide from a β-sheet to an α-helix:
a model for amyloid formation," Proceedings of the National Academy of Sciences, vol.
94, no. 1, pp. 23-28, 1997.
[126] J. Kong and S. Yu, "Fourier transform infrared spectroscopic analysis of protein
secondary structures," Acta biochimica et biophysica Sinica, vol. 39, no. 8, pp. 549-559,
2007.
[127] S. G. Kazarian and K. A. Chan, "Micro-and macro-attenuated total reflection Fourier
transform infrared spectroscopic imaging," Applied spectroscopy, vol. 64, no. 5, pp.
135A-152A, 2010.
[128] J. Pedersen, M. Coskun, C. Soendergaard, M. Salem, and O. H. Nielsen, "Inflammatory
pathways of importance for management of inflammatory bowel disease," World journal
of gastroenterology: WJG, vol. 20, no. 1, p. 64, 2014.
[129] L. Hancock and N. Mortensen, "How often do IBD patients require resection of their
intestine?," Inflammatory bowel diseases, vol. 14, no. suppl_2, pp. S68-S69, 2008.
[130] G. Bouguen and L. Peyrin-Biroulet, "Surgery for adult Crohn's disease: what is the actual
risk?," ed: BMJ Publishing Group, 2011.
[131] S. Rakoff-Nahoum, L. Hao, and R. Medzhitov, "Role of toll-like receptors in
spontaneous commensal-dependent colitis," Immunity, vol. 25, no. 2, pp. 319-329, 2006.
[132] E. Viennois et al., "Serum miRNA signature diagnoses and discriminates murine colitis
subtypes and predicts ulcerative colitis in humans," vol. 7, no. 1, pp. 1-16, 2017.
[133] M. Vijay-Kumar et al., "Metabolic syndrome and altered gut microbiota in mice lacking
Toll-like receptor 5," Science, vol. 328, no. 5975, pp. 228-231, 2010.
[134] J. Grdadolnik, "ATR-FTIR spectroscopy: Its advantage and limitations," Acta Chimica
Slovenica, vol. 49, no. 3, pp. 631-642, 2002.
[135] Å. Rinnan, F. van den Berg, and S. B. Engelsen, "Review of the most common preprocessing techniques for near-infrared spectra," TrAC Trends in Analytical Chemistry,
vol. 28, no. 10, pp. 1201-1222, 2009.
[136] Ø. Hammer, D. A. Harper, and P. D. J. P. e. Ryan, "PAST: Paleontological statistics
software package for education and data analysis," vol. 4, no. 1, p. 9, 2001.
[137] S. Wold, K. Esbensen, and P. Geladi, "Principal component analysis," Chemometrics and
intelligent laboratory systems, vol. 2, no. 1-3, pp. 37-52, 1987.
[138] J. J. Moré, "The Levenberg-Marquardt algorithm: implementation and theory," in
Numerical analysis: Springer, 1978, pp. 105-116.
[139] J. A. Pierce, R. S. Jackson, K. W. Van Every, P. R. Griffiths, and H. Gao, "Combined
deconvolution and curve fitting for quantitative analysis of unresolved spectral bands,"
Analytical Chemistry, vol. 62, no. 5, pp. 477-484, 1990.

90
[140] R. Sahu et al., "Characteristic absorbance of nucleic acids in the Mid-IR region as
possible common biomarkers for diagnosis of malignancy," vol. 3, no. 6, pp. 629-638,
2004.
[141] J. B. Reitsma, A. S. Glas, A. W. Rutjes, R. J. Scholten, P. M. Bossuyt, and A. H.
Zwinderman, "Bivariate analysis of sensitivity and specificity produces informative
summary measures in diagnostic reviews," Journal of clinical epidemiology, vol. 58, no.
10, pp. 982-990, 2005.
[142] A.-M. Šimundić, "Measures of diagnostic accuracy: basic definitions," Ejifcc, vol. 19, no.
4, p. 203, 2009.
[143] C. Petibois et al., "Determination of glucose in dried serum samples by Fourier-transform
infrared spectroscopy," Clinical chemistry, vol. 45, no. 9, pp. 1530-1535, 1999.
[144] A. Yamanaka, A. Hashimoto, T. Matsuo, M. Kanou, K.-I. Suehara, and T. Kameoka,
"Analysis of kinetic uptake phenomena of monosaccharide and disaccharide by
suspension TBY-2 cells using an FT-IR/ATR method," Bioprocess and biosystems
engineering, vol. 30, no. 6, pp. 457-468, 2007.
[145] P. G. Andrus and R. D. Strickland, "Cancer grading by Fourier transform infrared
spectroscopy," Biospectroscopy, vol. 4, no. 1, pp. 37-46, 1998.
[146] B. R. Wood, M. A. Quinn, F. R. Burden, and D. McNaughton, "An investigation into
FTIR spectroscopy as a biodiagnostic tool for cervical cancer," Biospectroscopy, vol. 2,
no. 3, pp. 143-153, 1996.
[147] G. I. Dovbeshko, N. Y. Gridina, E. B. Kruglova, and O. P. Pashchuk, "FTIR
spectroscopy studies of nucleic acid damage," Talanta, vol. 53, no. 1, pp. 233-246, 2000.
[148] P. Ramalingam, Y. P. Reddy, K. V. Kumar, B. R. Chandu, and K. Rajendran, "Evaluation
of metformin hydrochloride in Wistar rats by FTIR-ATR spectroscopy: A convenient tool
in the clinical study of diabetes," Journal of natural science, biology, and medicine, vol.
5, no. 2, p. 288, 2014.
[149] H. Fabian, M. Jackson, L. Murphy, P. H. Watson, I. Fichtner, and H. H. Mantsch, "A
comparative infrared spectroscopic study of human breast tumors and breast tumor cell
xenografts," Biospectroscopy, vol. 1, no. 1, pp. 37-45, 1995.
[150] J. Barahona-Garrido et al., "Serological markers in inflammatory bowel disease: a review
of their clinical utility," Revista de gastroenterologia de Mexico, vol. 74, no. 3, pp. 230237, 2009.
[151] E. A. Scoville et al., "Alterations in lipid, amino acid, and energy metabolism distinguish
Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic
profiling," Metabolomics, vol. 14, no. 1, p. 17, 2018.
[152] D. M. Wiese et al., "Serum fatty acids are correlated with inflammatory cytokines in
ulcerative colitis," PloS one, vol. 11, no. 5, p. e0156387, 2016.
[153] J. Ollesch, S. L. Drees, H. M. Heise, T. Behrens, T. Brüning, and K. Gerwert, "FTIR
spectroscopy of biofluids revisited: an automated approach to spectral biomarker
identification," Analyst, vol. 138, no. 14, pp. 4092-4102, 2013.
[154] L. Lovergne, G. Clemens, V. Untereiner, R. A. Lukaszweski, G. D. Sockalingum, and M.
J. Baker, "Investigating optimum sample preparation for infrared spectroscopic serum
diagnostics," Analytical Methods, vol. 7, no. 17, pp. 7140-7149, 2015.
[155] S. Yoshida et al., "Fourier transform infrared spectroscopic analysis of rat brain
microsomal membranes modified by dietary fatty acids: possible correlation with altered
learning behavior," Biospectroscopy, vol. 3, no. 4, pp. 281-290, 1997.

91
[156] K. A. Oberg, J. M. Ruysschaert, and E. Goormaghtigh, "The optimization of protein
secondary structure determination with infrared and circular dichroism spectra,"
European journal of biochemistry, vol. 271, no. 14, pp. 2937-2948, 2004.
[157] M. Meurens, J. Wallon, J. Tong, H. Noel, and J. Haot, "Breast cancer detection by
Fourier transform infrared spectrometry," Vibrational spectroscopy, vol. 10, no. 2, pp.
341-346, 1996.
[158] E. Gazi et al., "A correlation of FTIR spectra derived from prostate cancer biopsies with
Gleason grade and tumour stage," European urology, vol. 50, no. 4, pp. 750-761, 2006.
[159] K. Gajjar et al., "Diagnostic segregation of human brain tumours using Fourier-transform
infrared and/or Raman spectroscopy coupled with discriminant analysis," Analytical
Methods, vol. 5, no. 1, pp. 89-102, 2013.
[160] J. R. Hands et al., "Brain tumour differentiation: rapid stratified serum diagnostics via
attenuated total reflection Fourier-transform infrared spectroscopy," Journal of neurooncology, vol. 127, no. 3, pp. 463-472, 2016.
[161] J. R. Hands et al., "Attenuated total reflection Fourier transform infrared (ATR-FTIR)
spectral discrimination of brain tumour severity from serum samples," J. Biophotonics,
vol. 7, no. 3-4, pp. 189-199, 2014.
[162] M. Lens and J. Newton-Bishop, "An association between cutaneous melanoma and nonHodgkin's lymphoma: pooled analysis of published data with a review," Annals of
oncology, vol. 16, no. 3, pp. 460-465, 2005.
[163] Z. Hammody, R. K. Sahu, S. Mordechai, E. Cagnano, and S. Argov, "Characterization of
malignant melanoma using vibrational spectroscopy," The Scientific World Journal, vol.
5, pp. 173-182, 2005.
[164] E. Bogomolny, M. Huleihel, Y. Suproun, R. K. Sahu, and S. Mordechai, "Early spectral
changes of cellular malignant transformation using Fourier transform infrared
microspectroscopy," Journal of biomedical optics, vol. 12, no. 2, pp. 024003-024003-9,
2007.
[165] S. Mordechai et al., "Possible common biomarkers from FTIR microspectroscopy of
cervical cancer and melanoma," Journal of microscopy, vol. 215, no. 1, pp. 86-91, 2004.
[166] H. Ghazarian, B. Idoni, and S. B. Oppenheimer, "A glycobiology review: carbohydrates,
lectins and implications in cancer therapeutics," Acta histochemica, vol. 113, no. 3, pp.
236-247, 2011.
[167] E. Heitzer, P. Ulz, and J. B. Geigl, "Circulating tumor DNA as a liquid biopsy for
cancer," Clinical chemistry, vol. 61, no. 1, pp. 112-123, 2015.
[168] D. J. J. o. c. e. Swinehart, "The beer-lambert law," vol. 39, no. 7, p. 333, 1962.
[169] K. S. Schweizer and D. Chandler, "Vibrational dephasing and frequency shifts of
polyatomic molecules in solution," The Journal of Chemical Physics, vol. 76, no. 5, pp.
2296-2314, 1982.
[170] M.-C. W. Gast et al., "Serum protein profiling for diagnosis of breast cancer using
SELDI-TOF MS," vol. 22, no. 1, pp. 205-213, 2009.
[171] A. R. Green et al., "Barriers to screening colonoscopy for low-income Latino and white
patients in an urban community health center," Journal of general internal medicine, vol.
23, no. 6, pp. 834-840, 2008.
[172] J. Cohen, Statistical power analysis for the behavioral sciences. Academic press, 2013.
[173] M. Moscandrew, U. Mahadevan, and S. Kane, "General health maintenance in IBD,"
Inflammatory bowel diseases, vol. 15, no. 9, pp. 1399-1409, 2009.

92
[174] T. Castro Aguilar-Tablada, M. Navarro-Alarcón, J. Quesada Granados, C. Samaniego
Sánchez, J. Rufián-Henares, and F. Nogueras-Lopez, "Ulcerative colitis and Crohn’s
disease are associated with decreased serum selenium concentrations and increased
cardiovascular risk," Nutrients, vol. 8, no. 12, p. 780, 2016.
[175] E. Andersson et al., "Subphenotypes of inflammatory bowel disease are characterized by
specific serum protein profiles," PloS one, vol. 12, no. 10, p. e0186142, 2017.
[176] P. Vereecken, F. Cornelis, N. Van Baren, V. Vandersleyen, and J.-F. Baurain, "A
synopsis of serum biomarkers in cutaneous melanoma patients," Dermatology research
and practice, vol. 2012, 2012.
[177] E. Legouffe et al., "C-reactive protein serum level is a valuable and simple prognostic
marker in non Hodgkin's lymphoma," Leukemia & lymphoma, vol. 31, no. 3-4, pp. 351357, 1998.
[178] W. W. Overwijk and N. P. Restifo, "B16 as a mouse model for human melanoma,"
Current Protocols in Immunology, pp. 20.1. 1-20.1. 29, 2001.
[179] P. Jayaweera, S. Matsik, A. Perera, H. Liu, M. Buchanan, and Z. Wasilewski, "Uncooled
infrared detectors for 3–5 μ m and beyond," Applied Physics Letters, vol. 93, no. 2, p.
021105, 2008.
[180] H. Schwarzenbach and K. J. B. C. R. Pantel, "Circulating DNA as biomarker in breast
cancer," vol. 17, no. 1, p. 136, 2015.
[181] M. Kriege et al., "Factors affecting sensitivity and specificity of screening mammography
and MRI in women with an inherited risk for breast cancer," vol. 100, no. 1, pp. 109-119,
2006.
[182] M. J. N. E. J. M. Kriege, "Magnetic Resonance Imaging Screening Study Group. Efficacy
of MRI and mammography for breast-cancer screening in women with a familial or
genetic predisposition," vol. 351, pp. 427-437, 2004.
[183] M. S. G. J. T. Lancet, "Screening with magnetic resonance imaging and mammography
of a UK population at high familial risk of breast cancer: a prospective multicentre cohort
study (MARIBS)," vol. 365, no. 9473, pp. 1769-1778, 2005.
[184] J. M. Cameron, H. J. Butler, D. S. Palmer, and M. J. Baker, "Biofluid spectroscopic
disease diagnostics: A review on the processes and spectral impact of drying," Journal of
biophotonics, vol. 11, no. 4, p. e201700299, 2018.
[185] C. Hughes et al., "Assessing the challenges of Fourier transform infrared spectroscopic
analysis of blood serum," Journal of biophotonics, vol. 7, no. 3‐4, pp. 180-188, 2014.
[186] K. Gajjar et al., "Fourier-transform infrared spectroscopy coupled with a classification
machine for the analysis of blood plasma or serum: a novel diagnostic approach for
ovarian cancer," Analyst, vol. 138, no. 14, pp. 3917-3926, 2013.
[187] J. S. Koopmeiners and Z. Feng, "Asymptotic properties of the sequential empirical ROC,
PPV and NPV curves under case-control sampling," Annals of statistics, vol. 39, no. 6, p.
3234, 2011.
[188] J. A. Kimber, S. G. J. A. Kazarian, and b. chemistry, "Spectroscopic imaging of
biomaterials and biological systems with FTIR microscopy or with quantum cascade
lasers," vol. 409, no. 25, pp. 5813-5820, 2017.
[189] M. Koç and E. J. A. S. R. Karabudak, "History of spectroscopy and modern
micromachined disposable Si ATR-IR spectroscopy," vol. 53, no. 5, pp. 420-438, 2018.
[190] J. D. Hanna, J. I. Scheinman, and J. C. J. P. C. o. N. A. Chan, "The kidney in acid-base
balance," vol. 42, no. 6, pp. 1365-1395, 1995.

93
[191] M. A. J. A. N. Napierala, "What is the Bonferroni correction," vol. 6, no. 4, p. 40, 2012.
[192] R. Fluss, D. Faraggi, and B. J. B. J. J. o. M. M. i. B. Reiser, "Estimation of the Youden
Index and its associated cutoff point," vol. 47, no. 4, pp. 458-472, 2005.
[193] R. L. Baldwin and B. H. J. P. o. t. N. A. o. S. Zimm, "Are denatured proteins ever
random coils?," vol. 97, no. 23, pp. 12391-12392, 2000.
[194] M. Baldassarre, C. Li, N. Eremina, E. Goormaghtigh, and A. J. M. Barth, "Simultaneous
fitting of absorption spectra and their second derivatives for an improved analysis of
protein infrared spectra," vol. 20, no. 7, pp. 12599-12622, 2015.

94
APPENDICES
Appendix A
In this appendix, additional information on sample, study protocol and the discussion on
feasibility of technique in clinical domain is provided.
Appendix A.1 Understanding the Clinical Feasibility of Technique for Disease
Screening
ATR-FTIR spectroscopy has proven to be an excellent alternative for observing the biomolecular composition of body-fluids and their variations due to a myriad of pathologies[28].
Various studies have demonstrated the potential application of this technique in the forensic
sciences for the routine confirmatory screening of biological evidence[48]. Consequently, several
challenging aspects of the clinical applications of this technique have also been reported[184, 185];
thus, it is critical to have an in-depth understanding of these obstacles while developing a new
diagnostic regimen.
One of the most prevalent issues in the clinical application[185] of this technique is the
variation in the localized drying of the serum sample[184]. To address this, we have
experimentally demonstrated the effect of the “Air Drying of Serum Samples” as in Figure A1.
Major clinical feasibility parameters such as “Measurement to measurement” and “User to user
reproducibility” during the spectral measurements are further tested and outlined in Figure A2.
These studies show that the effect of localized drying phenomena of the sample on the ATR crystal
surface is negligible compared to disease-associated changes as reported elsewhere. Note that the
disease-associated alteration in the spectral data can be further optimized through the use of
spectral classification techniques[186].
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Furthermore, the user-friendly instrumentation, integrated with intelligent software
packages for presenting the diagnostic regimen, is necessary for the acceptance of the technique
as a possible technological development. A schematic of our instrumentation, accompanied with
our standard spectral analysis process of chain functionality, data records, averages,
normalizations, deconvolutions, and quantifications are briefly presented in our earlier study.
Air drying of serum samples: The drying phenomena of liquid droplets deposited on a
solid surface depends on various, complex physical mechanisms, including fluid dynamics,
properties of the liquid and contact surface, and heat transfer[184]. In the ATR sampling mode,
the drying of serum samples results in complicated patterns[185]. We have tested the drying
phenomena of the serum sample and their overall impact while comparing the composition within
the control and colitis samples as shown in Figure. A1. The serum sample deposited on the surface
was allowed to air dry at room temperature. Images (A-H) in Figure. A1 show the serum sample
throughout the drying process continues.
Figure. A1 (A) is the image after 4 minutes of its deposition, and the following images (BH) are at additional two-minute intervals. Figure. A1(I) shows the spectral data and their variation
with the sample crystallization: Spectra 1 represents the first spectra measured after 4 minutes of
sample deposition, 2 indicates the second spectra and 3 denote the third spectra. After 10 minutes
of sampling and 5 spectral scans, the absorption curve displays promising overlap. The inset I(i)
is the magnified view of the spectral range 3225-3350 cm-1, which is mainly comprised of water
content and proteins. Similarly, inset I(ii) is the magnified view of spectral range 1610-1670 cm-1,
a fraction of amide I region. The red dotted spectra show measurements before the sample has
stabilized, while solid blue lines are these spectra after the sample becomes stable. These spectral
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data and images clearly depict that the sample becomes stable on the crystal surface after
approximately 10 minutes.

Figure A1 (A-H) Microscopic images of one microliter serum sample during different
stages of drying at room temperature. Pictures (A) to (H) indicate the image of the serum in 2minute intervals starting with (A) 4 minutes after its deposition and (H) 18 minutes after
deposition. (I) FTIR spectra showing variation in absorbance during the air-drying of the serum
samples. Spectra representing 1 is the first spectra taken after 4 minutes of sample deposition, 2
is second spectra (~ 5.2 minutes), 3 is third spectra (~ 6.4 minutes). Overlapping spectra (solid

97
blue ▬) indicate the stabilization of the sample. Inset I(i) and I(ii) show the magnified view of
spectral range 3225-3350 cm-1 and 1610-1670 cm-1 to highlight spectral reproducibility nearly
after 10 minutes of sample deposition.

Measurement-to-measurement and user-to-user reproducibility: We have further tested the
measurement-to-measurement and user-to-user reproducibility as an important clinical feasibility
parameter. Three researchers took sampling and spectral measurements to test user-to-user
consistency. Likewise, the spectral measurements of twelve control and twelve diseased samples
were taken to observe measurement-to-measurement reproducibility. Figure. A2(A) shows the pvalue calculations, using the student’s t-test (two-tailed, unequal variance) of the serum spectra,
measured at two different times (the First and Second sets). Twelve measurements were taken
using both the same sample and protocol. These results did not indicate any statistically significant
wavenumber position differences from different measurements. Additionally, three different
researchers (1st, 2nd, and 3rd) took 12 individual measurements and found the P-values as seen in
Figure. A2(B). Similarly, we no statistically significant differences between spectral
measurements were found. These results suggest that the ATR-FTIR technique of serum
sampling/measuring offers a viable measurement-to-measurement reproducibility with minimal
user-to-user variations. In conclusion, these results suggest that, despite the complicated drying
phenomena of the serum samples, the measurement-to-measurement or user-to-user variation is
negligible compared to the difference between control and disease samples. Hence, the overall
spectral measurements affirm the technique as it verifies the clear similarity among the same types
of samples while discriminating between colitis and control samples.
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Figure A2 (A) Spectral discrimination by student’s t-test (with two-tailed unequal
variance) p-values of normalized absorbance using 12 measurements of the same sample at two
different times. P-values >> 0.05 clearly show the similarity between these spectra verifying better
measurement-to-measurement reproducibility of the technique. (B) P-values calculated for the
absorbance data measured by three different researchers. Significantly, similar p-values (p⩾ 0.18
>> 0.05) are found while comparing data from individual researchers, verifying the user-to-user
consistency.

Appendix A.2 Penetration depth of infrared light in the sera
In ATR-FTIR spectroscopy[28], the light is totally reflected inside the prism of the higher
refractive index with an evanescent wave from the reflected light penetrating into the serum
sample[30]. The penetration depth of evanescent waves on the sample medium is given by the
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equation, 𝑑𝑝 = 𝜆/2𝜋(µ1 2 𝑆𝑖𝑛2 𝜃 − µ2 2 )

1⁄
2,

which depends on the wavelength of incident

radiation (𝜆), the refractive index of crystal (µ1 ), the angle of incidence (𝜃), and the refractive
index of the sample (µ2 ). The energy of the evanescent wave is absorbed by the sample and the
reflected light is then coupled back into the system as shown in Figure. A3(A). The output spectra
represent a snapshot of the molecular component within the sample medium.

Figure A3 (A) Light-sample interaction and formation of evanescent wave in ATR
sampling mode. (B) Output spectra of 1𝛍l of serum samples using diamond and Silicon crystals.
Specifically, for serum samples, penetration of around 2 𝛍m can be achieved using
diamond crystals and with an angle of incidence equals to 45 degrees. Fig. S3(B) shows two output
spectra of 1 𝛍l of the same serum sample using two different ATR crystals, Diamond and Silicon.
These changes are due to the difference in the refractive indices of the materials of the two crystals.
Spectra obtained with the use of the diamond crystal in the mid-infrared region is best for clinical
application when compared with Silicon.
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Appendix A.3 Sample Size Estimation for Diagnostic Accuracy in Human IBD Samples
Using 18 UC and 28 Control human samples, the sensitivity and specificity values are 78%
and 82% for identifying spectral signature, ratio (α-helix/β-sheet). These indicate that the spectral
band ratio (α-helix/β-sheet) has high diagnostic accuracy in detecting colitis and is thus a good
signature while developing screening tool of colitis. We have compared different sample sizes by
using the power analysis and simulation study that is common in medical diagnostic trials[172]. At
a significance level α= 0.05 and power levels (1-β) = 0.90, the required sample size is 70 each
from control and disease groups (see table A1 as extracted from[172] and the initial values based
on asymptotic theory[187]) to achieve the continuous-scale spectral signatures to have specificity
82% and sensitivity 90%. These 70 diseased samples can be divided into 18 initial stages, 18
aggravated stages, 17 treatment phases and 17 healing phases. In the table, false positive fraction
(FPF) and true positive fraction (TPF) are used to find number of samples size.

Table A1 Estimated human sample sizes for continuous test using ROC (FPF0) as the basis
for inference with α = 0.05 and β = 0.10. Simulation studies were based on the binormal ROC
curve with slope parameter 1 and the initial values based on asymptotic theory.
FPF0,
FPF0
0.10,0.60
0.20, 0.70

.70
49

.80
20
44

TPF1
.90
1
0

Appendix A.4 Quantified Values at Spectral Signatures of UC Patients
Table A2 Quantified values of spectral signatures of UC patients. Shaded region of the
table highlights the data extracted from male patients and unshaded are from female. Variability
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of these signatures (I1033, I1076, I1121/I1020, I1629/I1737 and α/β) does not show age, gender, height,
weight, smoking and alcohol consumptions dependence in the uniform pattern, so a concluding
remark cannot be made.
Gender

Age

Male
Male
Male
Male
Male
Male
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female

34
41
49
55
63
71
21
27
46
47
55
59
60
63
65
65
82
91

Height Weight BMI
(inch)
72
72
71
70
69
68
65
66
66
64
66
64
66
67
65
62
66
66

254
240
185
224
166
189
136
185
145
155
135
170
205
187
163
256
200
130

34.4
32.5
25.8
32.1
24.5
28.7
22.6
29.9
23.4
26.6
21.8
30.1
33.1
31.1
27.1
46.8
32.3
21

Smoke Alcohol
N
N
Y
N
N
Y
Y
Y
Y
Y
N
Y
Y
N
N
N
N
Y

Y
Y
Y
Y
N
Y
N
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
N

I1033

I1076

I1121/
I1020

I1629/
I1737

α/β

0.2746
0.3252
0.2741
0.3263
0.2985
0.2746
0.3583
0.2769
0.2856
0.3103
0.2574
0.3212
0.2825
0.2646
0.3276
0.2896
0.3225
0.3753

0.3518
0.3908
0.3472
0.4058
0.3715
0.3537
0.4158
0.3422
0.3599
0.3809
0.3288
0.3953
0.3603
0.3409
0.3944
0.3639
0.3974
0.4161

1.4189
1.3069
1.4072
1.3965
1.3650
1.4459
1.2559
1.3803
1.4062
1.3763
1.4442
1.3565
1.4154
1.4372
1.3203
1.3665
1.2887
1.1647

29.1055
37.5426
32.7251
34.7197
36.6690
22.2489
33.7787
36.8969
29.5883
33.0132
34.8734
49.4526
21.6636
27.4452
46.3393
31.1652
30.2302
34.8415

1.9261
2.0303
2.2569
1.9682
2.0693
2.4699
1.9947
2.1782
2.0761
1.9962
2.0969
1.9258
2.0273
1.8955
2.1512
1.9071
2.0975
2.0337

The quantified values of identifying spectral signatures; I1033, I1076, I1121/I1020, I1629/I1737 and
α/β of UC patients are shown in Table A2. These data do not depend on the age, gender, height,
weight, smoking and alcohol consumptions of UC patients. However, while comparing with the
corresponding values with control samples tabulated (Table A3), statistically significance
difference can be seen, as discussed in the manuscript. These results show the identifying
signatures are due to UC.
Table A3 Quantified values of control samples at spectral marker signatures. Shaded
region of the table highlights the data extracted from male and unshaded are from female controls.
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Variability of these signatures (I1033, I1076, I1121/I1020, I1629/I1737 and α/β) does not show age and
gender dependence.
Gender
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female
Female

Age (year)
34
36
41
46
49
55
63
66
66
68
71
21
27
35
46
47
49
53
53
54
55
56
57
58
58
59
60
60

I1033
0.2439
0.2724
0.2986
0.2516
0.2687
0.2698
0.2994
0.2567
0.3056
0.2553
0.2612
0.3140
0.2634
0.2459
0.2699
0.2544
0.2592
0.2719
0.2587
0.2637
0.2814
0.3256
0.2645
0.2693
0.2757
0.2615
0.3000
0.3279

I1076
0.3309
0.3490
0.3699
0.3299
0.3574
0.3425
0.3704
0.3271
0.3897
0.3282
0.3346
0.3897
0.3419
0.3314
0.3459
0.3302
0.3249
0.3613
0.3249
0.3283
0.3503
0.3883
0.3363
0.3432
0.3474
0.3389
0.3776
0.4052

I1121/I1020
1.8472
1.5322
1.4209
1.5741
1.6699
1.4936
1.4425
1.5818
1.4194
1.5749
1.4868
1.3609
1.4890
1.5689
1.5567
1.4495
1.5289
1.6523
1.5686
1.5082
1.5092
1.2883
1.5441
1.4839
1.4383
1.4205
1.4245
1.5026

I1629/I1737
32.5201
20.6883
31.1015
28.0227
24.1412
30.7681
31.7300
31.9618
24.839
35.4579
30.8804
31.5131
23.4095
20.2486
32.7598
25.5301
33.3139
28.2439
29.2131
30.2426
32.0153
26.2872
24.9430
27.8657
34.5593
27.5615
28.6436
30.0617

α/β
2.2639
2.3639
2.1678
2.0996
2.5469
2.3792
2.2136
2.0859
2.4585
2.1917
1.9729
2.2088
2.1454
2.4533
2.2022
2.1306
2.0304
2.4533
1.9885
2.0919
2.2074
2.2108
2.2771
2.4098
2.3635
2.3013
2.2799
2.5008

103
Appendix B
In this appendix additional information about the cancer study are presented.
Appendix B.1 Information for BC Patients
Table A4 Information about the BC patients: Biopsy results such as Invasive lobular
carcinoma (ILC), Invasive ductal carcinoma (IDC), Ductal Carcinoma In-Situ (DCIS) confirmed
the BC diagnoses. The tumor grading assessment was performed based on the national cancer
institute (NCI) guidelines. Grade-2 denotes the intermediate grade or moderately differentiated
tumor, whereas grade-3 denotes a high grade or poorly differentiated tumor.
ID

1

2

3

4

5

6

7

8

9

10

Age
years
BMI

41.95

56.55

65.36

46.98

50.39

37.86

58.24

30.97

65.97

63.75

40.09

28.63

33.43

38.52

54.8

N/A

21.14

33.59

25.96

22.78

Menstrua
l Status

Premenopau
sal

Postmenop
ausal

Postmenop
ausal

N/A

N/A

Premenop
ausal

Unkn
own

Premenop
ausal

Postmenop
ausal

N/A

BC
Screening Screeni
Discovery
ng

Accide
ntal

Accid
ental

Screen
ing

Accide
ntal

Selfexam

Selfexam

Selfexam

Pain

History

No

No

No

No

No

Yes

No

No

Yes

Tumor
Size

.9 x .9 x 1
x 1.99x1. 5.3x3.
1.1cm
.8cm
82x1.14 9 cm
cm
Right
Right
Left
Right

2.5 cm

5 cm

2.4 x
2.1 cm

5.0 cm

Right

6.6 x
3.9 x
4.2 cm
Left

Left

Right

Left

7.0 x
5.3 x
3.7 cm
Left

IDC

IDC

IDC

IDC

IDC

IDC

3

3

3

3

2

3

Yes

No

No

Yes

No

No

Laterality
Biopsy
Biopsy
Results

ILC

Yes

IDC

IDC

IDC

Malignant 2
Grade

3

3

3

Lymph
Nodes

Yes

Yes

No

Yes

Type of Mastecto
Surgery
my

Mastect Mastect Partial
omy
omy
Maste
SLNB
ctomy
(lump
ectom
y)
SLNB

Maste Mastect Maste Partial Partial Mastec
ctomy
omy
ctomy Mastect Mastect tomy
ALND SLNB SLNB
omy
omy
SLNB
(lumpe (lumpe
ctomy) ctomy)
SLNB
SLNB
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Table A4. shows the BC patients’ clinical information. The age of BC patients ranges from
30 years to 65 years and the age of control volunteers lies within this interval (41 to 58 years). The
median age for BC patients and control volunteers remains similar; 53 years for BC and 52 years
for controls. All BC patients were triple-negative (the hormone receptor subtype; estrange receptor
(ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2/neu)
status was negative).
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Appendix C
This appendix provides the details of the study protocol.
Appendix C.1 Research Protocol
Sample handling, measurement, data analysis was carried out in accordance with
(university research) relevant guidelines and regulations. These regulations and the
appropriateness of all the selected parameters are step wise discussed as the laboratory protocols
while performing ATR-FTIR spectroscopy of serum samples for disease diagnostics. The
corresponding original files are in the subfolder of L-drive (L:\HemendraThesisMaterial\ ATRFTIR study of serum samples).
Spectrometer and parameter setting
1)

Spectrometer: The Bruker Vertex-70 FTIR spectrometer, with a KBr beam splitter

and Deuterated Tri-Glycine Sulfate (DTGS) detector, was used[3]. Here, the optimization of the
application requires the selection of various components such as: source (Hg light), optics,
electronics, beam splitter, and detector. The beam splitter transmits half of the radiation striking it
and reflects the other half and KBr is the most widely used material for the IR beam splitters with
coverage of 4000 – 400 cm-1 mid-IR spectral region. DTGS detector is a sensitive roomtemperature detector for mid-IR measurements. It uses temperature-sensitive ferroelectric crystals
of deuterated triglycine sulfate. The working principle of DTGS detector involves, as the
temperature and hence polarizability of the crystal’s changes (due to the absorption of IR radiation)
a charge is generated which is detected by two parallel electrodes. The deuterated form of the
crystals is used because they have a higher Curie point.
2)

ATR accessory: The MVP-Pro ATR accessory fitted with a diamond crystal (1

mm x 1.5 mm) configured to have a single reflection is used to provide high levels of output.
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Diamond has a smaller acceptance angle cone, which allows having a good optical design to extract
good spectra. Because of the strong, robust, and chemically inert feature of diamond, it is
considered as the best ATR crystal for routine measurements on biological samples[127].
Germanium ATR crystal allows higher spatial resolutions (at high magnification) because of its
higher refractive index (µ = 4), but the use of high-magnification mode lowers the signal to noise
ratio (SNR). Therefore, the germanium ATR crystal has not yet been used for the study of
biological mediums[188]. Silicon ATR crystals are also not favored due to lattice vibrations within
a biologically relevant region obscuring information below 1500 cm-1 wavenumber[189].
Conventional ATR crystals such as ZnS are not considered suitable for analyzing kidney excretes
of patients with acid-base imbalance[190].
3)

Apodization: It is an optical filtering technique and is widely used in recent

cameras as well. As in the cameras, we can set apodization in our spectroscope. Please be sure that
the application which helps us blur background and highlight only the object to be imaged (person
who will be in photo) is apodization. It removes the airy disks caused by diffraction around the
intensity peak and improves the focus. Herein, appodization is used to smooth the discontinuities
at the end of recorded time. Medium Blackman-Harris 3-Term apodization function is employed
to reduce noise without compromising resolution.
4)

Resolution and zero-filling factor: It is the ability to separate two spectral lines

that are very close in wavelength and it determines the maximum number of spectral peaks that
our spectrometer can resolve. FTIR spectrometer provides different options to change resolution,
and the change in resolution sets the change in travel distance of moving mirror. In the present
study, A resolution of 4 cm-1 and a zero-filling factor of 4 to provide the best resolution ability
(maximum signal-to-noise ratio). The 4 cm-1 resolution in the spectral data of range 400-4000 cm-
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1

means the system would be able to be resolving a maximum of 900 (4000-400=3600/4) individual

wavenumbers across the spectrum. By doing so, we can get the protein secondary structure
information and other spectral signatures appropriately. With a resolution of 8 cm-1, it is found that
this is not appropriate for secondary structural study, as second derivative spectra do not reflect
the accurate position of disordered protein structures. By reviewing earlier studies, performing
multiple studies, and acknowledging reviewers’ recommendations we have used resolution of 4
cm-1 and a zero-filling factor of 4, so that the spacing between each data point is 1 cm-1. We have
performed repeated measurements and extract information from several studies, including
references [23-25, 32], while selecting these parameters. This selection allows us to reduce noise,
and to analyze the spectral data without losing information during spectral deconvolution.
Resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1 resolution gives rise to missing
secondary structure information (spectral signatures show a lower degree of variability), while
using diamond ATR crystal configured to have a single reflection of incident IR radiation.
Therefore, a resolution of 4 cm-1 with a zero-filling factor of 4 to give a data spacing of 1 cm-1 is
used.
5)

Zero-filling factor: The zero-filling factor decreases the spacing between the data

points as obtained from the resolution. Simply saying it increases the array-size of the spectral
data. The zero-filling factor should follow (2n, n = 1, 2, 3,...).
6)

Aperture size: Aperture size is set to 2.5 mm for the detector response without

saturation. Detector saturation needs to be avoided, otherwise it will lead to “starvation”, causing
it to generate constant signals.
7)

Gas purging system: A Parker-Ballston gas purging system was also used to

maintain purified ambient air in the spectrometer.
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Sample Management
1)

While handling the biological samples in the laboratory, adherence to the university

guidelines will be absolutely required (Research Information - Georgia State Ahead (gsu.edu)).
The exact date/time to pick the sample from the collaborator or suppliers (companies) should be
scheduled earlier. The samples are stored in the freezer (at NSC room, Room Number 231) at a
temperature -80oC upon received.
2)

The availability of instruments, storage, and others is also checked before

scheduling meetings with collaborators or before buying samples or performing the measurements.
Necessary information was collected about the samples ahead so that we can set the measurement
parameters accordingly and continue measurement immediately.
3)

Samples were received in the labeled transparent storage containers kept

systematically in a paper box, plastic, or dried ice containers depending on the nature of the sample.
The storage condition is also checked with a colleague or with company representatives who had
collected these samples, before the measurement.
4)

Currently, the freezer at room 232 NSC (Dr. Hasting’s lab) is used to store samples.

Container tubes that are put in one column of paper or plastic box with the proper identification in
the top rack of the refrigerator (Marked/labeled paper box with the name). These samples were
stored properly (labeled/ marked) so that it could be safe while using the refrigerator by other
research groups as well.
5)

On the day of the measurements, sample storage container tubes with the sample

were kept above the ice for thawing. (Use white LIFOAM Boxes and you can get ice in the 2nd
floor of the Natural Science Center (NSC) (on the corridor back of Pete’s office, shop manager)
and 3rd (Undergraduate biology lab) floors of the same building. Since we are doing label-free
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analysis, so environmental conditions for all the measurements should be the same (i.e. all samples
should be dipped in ice immediately taking out from the freezer, before measurement). Multiple
freezing and unfreezing alter the protein structures, so it is highly recommended to finish all
measurements in one sitting).
6)

Other issues like the use of cooling gases, (such as He & N2), leaving the sample in

air, crowded environment of the lab is also taken care of as they are not appropriate for our study.
Personal Security and Waste Management
We are analyzing biological (Hazardous) samples, so extreme care is taken while handling
these samples and while managing related waste products including used gloves, cleaning wipes,
Pipette tips, glass needles.
1)

Gloves (sometimes masks and lab coats also) were used while handling samples,

Broken parts, and wastes such as plastic pipette tips, used gloves, glass pipette, Berkshire paper,
and others. Considering gloves could be the vectors for infection related to these diseases: colitis
and carcinogenesis, these should not be used when touching anything other than the samples (while
leaving the room and touching the door handle, mobile phones, computer, water bottle, etc.).
2)

All the used gloves, glass pieces, serum tubes, and wipe-papers are properly

managed in the appropriate container with biohazard red plastic bags which is kept in our lab
(Optoelectronics laboratory, 146/148 NSC, GSU).
3)

These waste items were collected in appropriate cardboard boxes as recommended

by university guideline and are safely discarded.

Spectral Response Measurements
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The spectral response measurements involve several steps as summarized in the video
movie (https://www.youtube.com/watch?v=vn1EQ8liI4g) Also I college link ?//
1)

Cleaning: The surface of ATR crystal was first cleaned with sterile phosphate-

buffered saline (SALINE) followed by ETHANOL. For the longevity of diamond crystal, we are
using Berkshire paper instead of other tissue papers. Wipe saline and ethanol by Berkshire papers
in an x pattern. Wipe only once in each direction so that other dust molecules attached to the crystal
surface will be absorbed.
Note: Change pipette needles fixed with rubber suction for every new experiment (sample)
to avoid contamination, and gently press the rubber vacuum suction (pump) to pump SALINE and
ETHANOL. Otherwise, it will come up to rubber surface from the pipette tip and increases the
chance of contamination.
2)

The cleanliness test was then conducted to ensure there are no signal peaks

(indicating serum residue or other contaminant signatures) higher than the environmental noise
level. (Just click on the cleanliness test option). Make sure the light signal path includes the ATR
crystal.
3)

The Background: Before any experimental measurement, background spectra

were measured. The background spectrum allows us to get the true values of absorption peaks due
to molecules present in the sample. Background shows the presence of any environmental residue
on the crystal surface or in the light path. The spectrum was performed on a clean and empty
surface before each measurement. It allows us to get high-quality spectra using background
corrections.
4)

Background Measurement: Open OPUS, by double clicking it. A small window

will open and use User ID: UPLab1 and Password: OPUS to open.
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Again, follow the video if there is any confusion during any step of the measurements.
https://www.youtube.com/watch?v=vn1EQ8liI4g Also I college
Press Measure and then repeated measurement. Select, Advanced and choose the path
where you want to save the date. Remove tick mark on the ATR spectra box of data blocks, for
background measurement. Fix other parameters like wave number, scan and go back to the Basic
tab. You will see a repeated sample single channel (lower one). After pressing the repeated
sample single channel, you will see the IR spectra. Whenever the graphs of spectra start to overlap
stop the measurement by pressing Abort (right click the green line on the bottom of windows).
5)

Sample measurement: Load the desired amount of sample (I found 1µl is enough

to cover the ATR crystal) over the crystal plate by using Gilson micropipette carefully. In every
measurement, sample should have a similar droplet dimension. Also, take care of other
environmental factors like temperature, pressure, amount of light and other settings (all the
background conditions) should be similar for every measurement).
Note: Serum samples (1 µL) are deposited in order to fully cover the crystal surface (I tried
with 2 µL and 0.5 µL samples and found 1 µL is the best option).
After loading the sample, click the Advanced button and tick the ATR spectrum, select
the path, you could change the name from the background you used previously to a new name
clearly indicating sample identification information. Click on Background you will see an
arbitrary previous file already selected. Clear (delete) this old background and select the last
background you took (i.e. the curve just before pressing the abort button). After choosing the
background, double click load background. Return to the basic button and start scanning by
pressing the Repeated sample single channel, you will get the IR spectra. Stop your measurement
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by pressing the Abort button, if you find spectra starts to repeat itself and you have more than
eight overlapping spectra.
6)

Averaging: Take the average of 6 spectra (Referring: Bayesian statistics), which

were repeated (i.e. Exactly overlapped) after the serum dries measuring. Each sample was scanned
multiple times to get ten or higher-quality (exactly overlapping) spectral data within the midinfrared range 400 to 4000 cm-1 and 6 reads of the 100 co-added scans for each sample (total of
600 scans) were averaged.
7)

Number of Scans: Generally, the trend is for the number of scans to go as 2n (n =

2, 3,4,5…), but we are taking 100 scans for each spectral data. Thus, in each spectrum that are
selected for the final analysis represents (6x100) 600 scans. There is not any scientific reason for
this selection of 100 scans, but my recommendation is use scan 64 instead of 100. (Our experience
is by choosing 32 scans, will result into noisy spectra, and using 128 scans will take time, so my
recommendation is to use 64 scans). Depending on the laboratory conditions, these numbers may
be different. It is thus strongly recommended to check whether everything is ok before going to
actual measurements.
8)

Spectra saving: If you think you got the best spectra that can represent your

sample, go to file, save as, mode Data Point Table (.dpt), File name and path, Open them in Excel
you will get the a set of data, so select columns (A and B), go to Data, text to the column, next,
comma, next, finish.
9)

Normalization: Normalization is a crucial process while analyzing IR spectral data

of the present study, as they were recorded under different sample loading, which is influenced by
fluid dynamics of sample, and drying of sample conditions. Spectral data of the serum samples
could have different intensity levels. Normalization takes care of variation in IR bands of serum
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as the spectra were recorded under the same experimental parameters. Herein, Min-max
normalization of absorbance spectra and the vector normalization of second derivatives spectra
were performed. Using OPUS 6.5 software, all the spectra were min-max normalized by scaling
the range 1800 to 900 cm-1. This range is chooses as it comprises a significant biochemical
fingerprint of the biological material and the amides (I and II) bands[24].
Vector normalization[135] is another popular protocol. We are using min-max
normalization in absorbance spectra and vector normalization in second derivative spectra. In the
following points, I have explained the basic concept of these normalization and mathematical
formulation, so that one can use desired mathematical programming knowledge while normalizing
these data.
10)

Min-max normalization: Assuming absorbance values (before normalization) are

X = x1,x2,x3,x4,…. xn. Find the maximum of them and say Xmax and minimum as Xmin. MinMax normalized values are now;
𝑋𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = 𝑥

𝑥𝑖 −𝑥𝑚𝑖𝑛
𝑚𝑎𝑥 −𝑥𝑚𝑖𝑛

i = 1, 2, 3, …., N.

The min-max normalized data using this formula is compared as in figure A4 (A) with
normalized data using OPUS, which guarantees our formula can be used while using other
programming languages.
11)

Vector normalization: Assuming absorbance values (before normalization) are X

= x1,x2,x3,x4,…. xn.
First, find the square of each variable as (x1)2, (x2)2, (x3)2,…. (xn)2. After finding the
square of variables find the sum of them as; S = (x1)2 + (x2)2 + (x3)2 +…. + (xn)2. Again, find the
square root of S, which is also called norm of variable of X. Now vector normalized data are now;
𝑋𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 =

𝑥𝑖
√𝑆

i = 1, 2, 3, …., N.
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The vector normalized data using this formula is compared as in figure A4 (B) with
normalized data using OPUS, which guarantees our formula can be used while using other
programming languages.

Figure A4 Verifications of mathematical formula for normalization. (A) Min-max
normalization of absorption spectra. (B) Vector normalization of second derivative curves of the
spectra. Spectra obtained from the formula overlaps with the corresponding spectra, as obtained
from the OPUS software. It verifies, these formulas can be used while writing code in another
programming language.
12)

Smoothing: The second derivatives of Infrared spectra need smoothing.

The number of data in the absorption curve and the second derivatives curves are equal, so
by smoothing the number of data points will be same.

Let's say you have data Y =

(a,b,c,d,e,f,g,h……..z) (i.e. total set of data =26). Now you want to have a smoothed set of data Y’
= (a’, b’, c’, d’, …… z’). Here, a’ = (a), b’ = (a+b+c)/3, c’ = (a+b+c+d+e)/5, d’ =
(a+b+c+d+e+f+g)/7, e’ = (a+b+c+d+e+f+g+h+i)/9, f’ = (b+c+d+e+f+g+h+i+j)/9, ………… q’ =
(m+n+o+p+q+r+s+t+u)/9,

r’

=

(n+o+p+q+r+s+t+u+v)/9,

…………,

v’

=

(r+s+t+u+v+w+x+y+z)/9, w’ = (t+u+v+w+x+y+z)/7…….. y’ = (x+y+z)/3, z’ =z. We have nearly
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3500 sets of data and those crucial for our study lie in the middle, so no need to worry about these
numbers in the extreme.
It is noted that we have to smooth only second derivative spectra. In OPUS software, while
doing second derivatives, there are 9-point smoothing, 12-point smoothing, …. options. We cannot
get second derivative spectra without smoothing in this software (Note: there is no option available
to get second derivative spectra without smoothing). Herein, nine-point smoothing is used while
taking the second derivative spectra. For clarification, a smoothed and unsmoothed spectral data
using the vector normalized second derivative spectra is shown in figure A5. It is strongly
recommended to use data before cutting 900-1800 cm-1, as end points are affected during
smoothing. We can use Adjacent averaging, as explained above or Savitzky-Golay smoothing
function. The programming languages like Python are using Savitzky-Golay smoothing.
Look at the left side of the window and change the color of 2-3 last spectra so that you can
see the difference clearly. If you think you got the best spectra that can represent your sample, go
to file, save as, mode Data Point Table (.dpt), File name and path, open them in Excel you will get
the sticking set of data, so select columns (A and B), go to Data, text to the column, next, comma,
next, finish. The screen shot of each step is in the PPT of the folder.
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Figure A5 Spectral data before and after smoothing.
Data Analysis
The details of spectral analysis techniques are explained in the appropriate section of this
dissertation.
1)

First, the spectral data of the control and diseased samples within 400-4000 cm-1

wavenumber range. This mid-IR range includes bio fingerprint region (900-1500 cm-1) and amide
peaks (1500-1700 cm-1).
2)

Take the average of the final 6 spectra which are overlapped with each other (The

sample size of at least 6 is needed for meaning full statistical analysis).
P-value calculation of min-max normalized absorbance: The spectral data of two groups
(let’s say control and diseased) were first compared using student t-test p-values. In this study we
are using EXCEL to calculate the p-values and find the p-values at all the wavenumber positions.
3)

Take the second derivatives with 9 point smoothing and do the vector normalize

them to get the idea of minima and maxima of the data (that will be useful while fitting), for
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Dendrogram tree diagram plot[63] and PCA[137]. Now vector normalized[135] the second
derivatives curves.
4)

Hierarchical Cluster Analysis (HCA) and Dendrogram Plot: Our analysis includes

the dendrogram of HCA, which is commonly employed to identify the similarities between the
FTIR spectra by using the distances between frequencies and aggregation algorithms[63]. Using
the “PAST (Paleontological Statistics) 4 - the Past of the Future” software and the vector
normalized second derivative curve of the absorbance spectra, as input data (variables), HCA is
performed and the dendrogram is plotted. Dendrogram tree diagram performed, using Ward’s
algorithm and Euclidian distance measurements, allow us to visualize the overall classification.
Origin and MATLAB programming were also used for cluster analysis; however, use of PAST-4
is easy and has necessary inbuilt functions.

Figure A6 Dendrogram tree diagram performed, by using Ward’s algorithm and Euclidian
distance measurements of vector normalized second derivatives curves within spectral range
1600-1700 cm-1. (A) A wide difference can be seen between spectra belonging to control and colitis
mouse, compared to the degree of the dissimilarity between controls and treated while considering
three groups constraints (1 for control: c1 to c9, 2 for treated: t1 to t9, and 3 colitis: d1 to d9). (B)
Stratigraphic constraints of three groups showing colitis group has larger heterogeneity form

118
control and treated groups. While there is a similarity between control and treated groups in this
classification.
Dendrogram tree diagram performed, using Ward’s algorithm and Euclidian distance
measurements, allow us to visualize the overall classification as shown in figure A6. In both
analyses, spectral data from an equal number of mice were used (herein, we have randomly picked
9 controls). However, the degree of heterogeneity is less for treated groups from control compared
with colitis while using group constraints as in figure 6A (A). Similarly, only colitis group shows
strong degree of heterogeneity compared to control and treated groups in stratigraphic constraints.
Herein, HCA analysis allows us to understand the preliminary idea about the potential application
of the measurement techniques to segregate the groups.
5)

PCA: PCA[137], a useful statistical analysis[137], is first performed to explain the

holistic evaluation biomolecular content variations reflected in infrared absorbance data. Using the
PAST 4 software vector normalized second derivative curve of the absorbance spectra, as input
data variables, the variance-covariance matrix with the pairwise exclusion of missing values were
analyzed to get the component plots. This can also be done easily by using Origin and SPSS
software, but PAST-4 is easier one. The scatter plot of PC1 and PC2 were used to visualize the
clustering of groups together with different magnitudes and directions. The scree plot is also used
to check the total variance presented by PC1 and PC2 is significant. These findings from the PCA
analysis led us to investigate spectral signatures useful in the clinical domain.
6)

Spectral Deconvolution (fitting):

Watch the video first (https://www.youtube.com/watch?v=zGHP2GBBdnE) and look into
section 2.4.3, figure 2.1 for details.
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We perform quantitative analysis of the absorption band values at different spectral
markers’ positions, which follows discrimination of secondary structures by deconvolution of the
spectra in the amide I region. During the deconvolution process, the computed curve that best fit
with the experimental spectrum is obtained from the superposition of Gaussian function energy
bands (GFEB). The individual bands from deconvolution represent proteins’ secondary structures
as discussed in the protocol papers, and similar studies in the field[108, 116-118, 120, 126] which
were used to verify the applicability of this technique over complementary spectroscopic methods
(X-ray crystallography, and nuclear magnetic resonance).
The process of deconvolution includes sectioning of min-max normalized spectra followed
by rubber-band correction with two baseline points, such that absorbance values at extreme ends
of the selected region will be zero as in figure A6. These spectra were then fitted with GFEBs by
approximating the position and the number of bands from the minima of second derivative spectra
and also by the minimization of root mean square error via the Levenberg-Marquardt[138]
algorithm.

Figure A7 The process of rubber band baseline correction. The sectioned region 16001700 cm-1 is baseline corrected using baseline correction, such that the absorbance at the two
extreme ends is 0.
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7)

Statistical Analysis: First, student’s t-test is performed in EXCEL to calculate the

p-value. P-value less than 0.05 (5% in Gaussian distribution) is considered as statistically
significant in the null hypothesis. It is noted that Bonferroni correction[191] (new p-value, which
is defined as the ratio of original p-value divided by the number of tests) is also performed to adjust
type I error[191] (that has higher chances for a false positive; example includes analysis is showing
differences in similar population due to problematic measurement or analyzing techniques) when
conducting multiple analysis. It is noted that, using this new p-value, researchers calculate
statistical power of the study.
Sensitivity, specificity the receiver operating characteristic (ROC) curves: Quantified
values of these identifying spectral signatures are statistically analyzed to see the diseaseassociated alteration in the sample, and their stabilization after biological therapy. Our statistical
analysis mainly includes finding the sensitivity and specificity of the signatures for their
discrimination. Sensitivity and Specificity of a diagnostic test are often used to describe the
diagnostic accuracy/performance of the analysis in biomedical research[141]. The discriminating
potential of a diagnostic regimen can be quantified by the Youden index and the area under the
receiver operating characteristic (ROC) curves [142]. The ROC curve is plotted to find the area
under curve (AUC). The optimal cutoff value calculated based on the Youden index for each
spectral marker is used to select the positivity/negativity of the disease and to estimate the
sensitivity and specificity. Youden Index summarizes the displaying discriminatory accuracy of a
diagnostic test in ROC curve while distinguishing two populations. It measures the effectiveness
of test and enables for selection of optimal cut-off value[192].
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Appendix D
In this appendix, information about the second derivative spectra is discussed.
Appendix D.1 Second Derivatives Spectra and Their Importance
In IR spectroscopy, molecules absorb light at resonance frequencies that are the
characteristic of molecular structure. Where, the energy of vibration depends on molecular shape
(potential energy), mass of atoms and the associated vibronic coupling (bonding)[3]. Therefore,
the observed profile is a convolution of the line profiles of each individual mechanism of
component constituents. The overall contribution of these individual vibrations is reflected in
infrared absorbance spectra. Essentially, absorption spectrum is the analysis of the IR light
interacting with molecules and is visualized in the graph of light absorption on the vertical axis vs
wavenumber (or wavelength) in horizontal axis.
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Figure A8 Derivative spectra and their importance for spectral analysis. (A) Gaussian
function distribution. (B) First derivative spectra and (C) Second derivative spectra. The minima
position of second derivative spectra exactly represents the maxima of Gaussian Distribution.

The line profiles, which have the shapes of Gaussian, Lorentzian and Voigt functions,
represent the vibration of individual components and depends on the line position, maximum
height and half-width. Therefore, curve fitting with these line shapes is sometime preformed either
for interpolation, or to find the contribution of individual components. The Gaussian distribution
(function) is used to explain the importance of second derivatives as in figure A7 (A). The first
and second derivatives of the Gaussian curve are shown figure A7 (B) and figure A7 (C),
respectively. The minima of second derivative curves exactly represents the maxima of Gaussian
curve, so minima of second derivatives are used to approximate the number and position of
GFEB’s used to fit the spectra in our study. These second derivatives data also offer a practical
and more specific method than routinely used absorption spectrum analysis to obtain the
composition of proteins and nucleic acids. Therefore, second derivative curves are also used in
PCA analysis and the dendrogram plots.
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Appendix E
In this appendix, selection of the number of GFEBs (oscillators) for fitting the experimental
absorbance curves is discussed. Second derivative spectra fitting reflecting the position of protein
secondary structures is also discussed.
Appendix E.1 Number of GFEBs (oscillators)
In IR spectroscopy, the spectra were fitted in general with GFEBs by approximating the
position and the number of bands from the minima of second derivative spectra and by the
minimization of root mean square error. ATR-FTIR spectra taken at resolution 8 cm-1, of air-dried
serum sample at room temperature clearly depicts four valley positions [figure A9(A)] in the
second derivative spectra showing significant presence of side chain, α-helix, β-sheet and β (anti//+turn) structures. Random coil is an integral unit of a protein structures their contribution is
significant in denatured proteins[193] analysis. However, the sera samples used in our study do
not have denatured proteins, and our spectra were showing its impact on the infrared absorption is
negligible compared to other four identified components. It is noted that the denaturation of
proteins occurs at high temperatures or chemical interactions[193]. In order to be consistent, our
analysis also includes an additional Gaussian band nearly at 1641 cm-1 reflecting random coil
structures in protein secondary structures. Figure A9(B) and figure A9(C) shows the experimental
curve fitting using GFEBs without (n=4) and with (n=5) the inclusion of random coil structures.
This additional band does not alter the sensitivity or specificity of the identified distinguishing
markers. Once the band at 1641 cm-1 is included, there is a slight variation in spectral signatures
(specially, alpha helix/beta sheet) but the pattern of colitis in contrast to non-colitis remains the
same as discussed, where absorbance spectra were measured at 8cm-1 resolution[4, 5].
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Figure A9 (A) Second derivative of ATR-FTIR absorbance of control sera at resolution 8
cm-1, showing the deconvolved amide I region. (B) The individual secondary structure components
were modeled using GFEB whose positions were determined from the second derivative of the
absorbance to obtain simulated fits to the experimental curves. (C) Secondary structures were
modeled using GFEB with the inclusion of random coil components approximately at wavenumber
position 1641 cm-1 [4].
Importantly, with a resolution of 2 cm-1 gives noisy derivative spectra and of 8 cm-1
resolution gives rise to missing secondary structure information (spectral signatures show a lower
degree of variability), while using diamond ATR crystal configured to have a single reflection of

125
incident IR radiation. By understanding of the positives and negatives of the techniques[122], and
their optimizations protocols[123], we found that a resolution of 4 cm-1 allows us to overcome the
challenges[139] of deconvolution process for quantitative analysis. At this resolution, two
individual band positions for β-sheet (anti-//) and β-turn are reflected in the second derivative
spectra. It further allows us to reduce the interspacing distance between bands. Increased spacing
between individual bands is considered as one of the challenging aspect of fitting technique[139].
Figure A10 (A) shows the second derivative spectra of absorbance spectra of air-dried serum
sample at resolution 4 cm-1. The minima/valley positions in the second derivative spectra showing
significant presence of side chain, α-helix, β-sheet, β-sheet (anti-//) and β-turn structures.

Figure A10 (A) Second derivative of ATR-FTIR absorbance of control sera at resolution
4 cm-1, showing amide I, region fitting. (B) The individual secondary structure components were
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modeled using GFEB whose positions were determined from the second derivative of the
absorbance to obtain simulated fits to the experimental curves. (C) Secondary structures were
modeled using GFEB with the inclusion of random coil components.
Experimental absorbance spectra taken at 4 cm-1 resolution were now fitted with (figure
A10 (C)) and without (figure A10 (B)) random coil structures. The integral ratio of α-helix and βsheet protein secondary structures with and without inclusion of random coil structure is analyzed
using BC data presented on section 3.3 (Figures 3.13 to figure 3.15 above). Figure A11 (A) and
figure A11 (B) are showing the ratio of the α-helix and β-sheet structures with and without
including random coils in the fitting. Both figures show the level of β sheet structure increase and
α helix decrease due to BC.

Figure A11 The integral ratio of α-helix and β-sheet protein secondary structures using
five and six bands on experimental curves at resolution 4 cm-1. (A) Ratio of integral values while
fitting experimental curve without random coils structures. (B) Ratio of integral values while
fitting experimental curves with including random coils structures.
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Appendix E.2 Estimation of Bands’ Position Using Second Derivatives Spectra Fitting
The second derivatives of absorbance spectra were also used to extract protein secondary
structural information reflected in infrared spectral data[194]. The local minima position of the
second derivative curves of the absorbance spectra provides the position of GFEB bands while
analyzing absorbance data. Figure A12 shows the techniques for the estimation of the band's
position using the second derivative fitting. Figure A12 (A) shows the second derivative spectra
of the experimental absorbance spectrum. The values of the second derivative spectra were
subtracted from 1 (Figure A12 (B)) at each wavenumber position and were rubber band corrected
(Figure A12 (C)). Thus obtained rubber band corrected spectra are then fitted with Gussiand bands
as shown in figure A12 (D). These second derivative spectral fitting offers a practical method to
obtain supporting information about the chemical composition within the sample. However, the
second derivative spectra may not provide all the biochemical components, like random coil
structures; in the considered range as discussed above (figure A9-figure A11). It could be due to
various reasons such as negligible presence of such protein structures or negligible contribution of
the constituents for bonding vibrations.
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Figure A12 Second derivative curve fitting technique. (A) Second derivative spectra. (B)
Values of second derivative spectra subtracted from one at each wavenumber position. (C) Rubber
band correction of the curve obtained from one minus second derivative. (D) GFEBs fitting to
estimate the position of the bands.

